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ABSTRACT
CONGENIC AND FUNCTIONAL ANALYSIS OF RAT MAMMARY CANCER
SUSCEPTIBILITY
Saasha Le
April 13th, 2016
Breast cancer is a complex disease affected by genetic, epigenetic and environmental
factors. The genetic architecture of breast cancer comprises of high to low penetrance alleles.
Although low penetrance alleles associate with a small change in an individual’s risk to breast
cancer, the total number of variants present and the high population frequency attributes to a
much greater population based impact compared to rare high penetrance alleles. Animal models
have been used to study these low penetrance modifier alleles in breast cancer. Different rat
strains vary in their susceptibility to 7,12- dimethybenzanthracene (DMBA) induced mammary
carcinogenesis, with the Wistar- Furth (WF) rat being highly susceptible and the Copenhagen
(Cop) strain being almost completely resistant to it. Linkage analysis performed to identify
quantitative trait loci associated with DMBA induced mammary carcinoma susceptibility in the
WF and Cop rats led to the identification of mammary carcinoma susceptibility loci 1-4 (Mcs1-4).
This dissertation focuses on Mcs3 and Mcs1b. The Mcs3 locus was predicted across two peak
marker on chromosome 1 D1Mit11 and D1Wox6. My work helped to physically confirm the
Mcs3 locus and map it to a 25.8 Mb region on rat chromosome 1. The Mcs1b locus was mapped
to a 1.8MB region on rat chromosome 2. denDekker et al 2012, showed that the Mcs1b locus and
identified Mier3 as an Mcs1b candidate gene. My studies showed, the proportion of luminal
mammary epithelial cells (MECs) was higher in Mcs1b resistant mammary epithelial cell
enriched extracts (MEC extracts) compared to susceptible MEC extracts. This observation
v

suggests that luminal MECs are potentially the target cells of DMBA induced carcinogenesis and
future mechanistic studies could be conducted in luminal MECs. Expression assays on MEC
extracts suggest that Mitogen-Activated Protein Kinase Kinase Kinase 1 (Map3k1), GC-Rich
Promoter Binding Protein 1 (Gpbp1) and Mesoderm Induction Early Response 1, Family
Member 3 alternative 5’ start site variant (Mier3-alt5P) are Mcs1b candidate genes.
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CHAPTER I
INTRODUCTION
Breast Cancer Statistics
According to cancer statistics for 2016, breast cancer was the most frequently
diagnosed cancer among women, preceded only by skin cancer, accounting for 231,840
new cases or 29% of cancer diagnosed [1]. A woman’s risk of being diagnosed with
breast cancer has increased from 1 in 11 in the 1970s to 1 in 8 in 2015. There are many
factors contributing to the increase in breast cancer risk, which include longer life
expectancy, and earlier diagnosis due to prophylactic measure [2]. Current and past
research has focused on the detection and treatment of this disease, leading to a 34% drop
in death rates since the 1990s [2]. However, despite these achievements, breast cancer
remains the second leading cause of cancer-related death among women, accounting for
15% of cancer-related death or 40,290 cases [3]. Thus, there is a need for further research
to understand the mechanism, and to identify risk factors associated with the
development of breast cancer.
Breast Cancer Risk Factors
Breast cancer is a complex disease controlled by environmental, genetic and
epigenetic factors [2]. An individual’s risk to breast cancer is determined by many
factors, including gender, age, family history, reproductive history, diet, alcohol use,
lifestyle and environmental exposure [2, 4]. Gender accounts for the largest portion ofrisk
to developing breast cancer, with women being more susceptible to breast cancer than
men. Female breast cancer accounts for 99% of breast cancer cases diagnosed and breast
1

cancer-related deaths [3]. The following text will discuss some factors contributing to
breast cancer risk in more detail.
Age
It is very uncommon for a woman in her 20s to be diagnosed with breast cancer,
but risk increases with age and the probability of a woman developing breast cancer in
her 90s being 1 in 5 [2, 5]. The prevalence of breast cancer is less than 10 cases per
100,000 for women under the age of 25 years. This prevalence increases 100-fold by the
age of 45, making it the leading cause of cancer-related death in women between the ages
of 20 to 59 [3, 6]. Breast cancer etiology varies with age. Although young women are less
likely to develop tumors, the tumors that they do develop tend to be more aggressive.
Younger women develop more estrogen receptor (ER)-negative tumors compared to
older women. This trend continues until about 60 years of age [7-9]. It was also found
that, for women above the age of 60, luminal A is the most common breast cancer
subtype, while in women below the age of 40, luminal A is the least common subtype [3,
10]. Thus, age is not only an important factor in the development of breast cancer, but
also in the prognosis and treatment of disease.
Radiation
Radiation exposure is also a strong risk factor for breast cancer, since breast tissue
is very sensitive to radiation-induced carcinogenesis [11]. The current understanding of
the relationship between ionizing radiation exposure and breast cancer risk was obtained
from epidemiological studies of patients exposed to radiation for medical treatment and
women exposed due to proximity to atomic bomb explosions [11, 12]. Age at exposure is
inversely related to risk of developing breast cancer. This is thought to stem from the
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degree of differentiation of breast tissue at age of exposure. In support, women below the
age of 20 are more susceptible than women above the age of 45 [12, 13]. It was also
found that the risk of developing breast cancer is proportional to the dose of radiation
exposure [12, 14]. However, studies have shown that low-dose radiation, delivered over a
period of time, e.g. under medical setting, can also have a long lasting cumulative effect
that may cause breast cancer [13, 14]. Medical use of radiation is recommended only
when the benefits outweigh the risks of exposure [15].
Alcohol Use
A number of epidemiological studies have shown that alcohol consumption
increases breast cancer risk [16-23]. Results of two meta-analyses suggest that an
addition of 10 g of alcohol per day increases risk of breast cancer by 10% [24, 25]. It is
worth noting that alcohol consumption is a risk factor associated with ER+ tumors [26,
27]. The mechanism behind alcohol consumption and breast cancer development is not
clearly understood. One hypothesis proposed is that alcohol contribute to breast cancer
development by modulating sex hormone levels in women [28]. Another hypothesis
proposed is that acetaldehyde, a known product of alcohol metabolism, is actually the
main contributor to alcohol-induced carcinogenesis [29, 30]. Alcohol is an organic lipid
solvent. Another theory proposed is that it may increase cell permeability to carcinogens
by modulating cell membrane properties. Alcohol has also been shown to impair folate
metabolism, thus influencing DNA methylation. Folate plays an important role in DNA
methylation [29]. Alcohol intake may also enhance reactive oxygen species (ROS)
production, modulate carcinogen metabolism, and inhibit DNA repair [31]. In part
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because of the risk between alcohol consumption and breast cancer development, women
are recommended to drink alcohol in moderation 1 drink/day [32].
Smoking
Studies have shown smoking increases breast cancer risk by 10% [33, 34]. It was
found that a woman has a higher risk if they started smoking many years prior to first
pregnancy [34-37]. Results from the Canadian National Breast Screening Study (NBSS)
indicate that breast cancer is associated with duration (40 years vs nonsmoker) of
cigarette smoking, with a hazards ratio (HR) of 1.57 (95% CI = 1.29 – 1.92). The HR for
the intensity (40 cigarettes per day vs nonsmoker) of cigarette smoking was 1.21 (95% CI
= 1.04 – 1.40). Breast cancer was also found to be associated with cumulative exposure
(40 pack years vs nonsmoker: HR = 1.09; 95% CI = 1.06 – 1.13) and latency (40 years
since initiation vs nonsmoker: HR = 1.31; 95% CI = 1.10 – 1.53) of cigarette smoking
[38]. Breast cancer is not historically considered a tobacco related cancer, but in vivo and
in vitro studies have implicated cigarette smoke induces breast carcinogenesis [39].
Cigarette smoke has many well documented carcinogens, and mammary tissue is capable
of taking up many of these carcinogens, including polycyclic aromatic hydrocarbons and
N-nitrosamines [40]. Mammary epithelial cells (MECs) are capable of bio-activating
these compounds into molecules that induce DNA-damage and -adduct formation [37,
41]. N-acetyltransferase-2 (NAT2) is a polymorphic enzyme responsible for detoxifying
aromatic and heterocyclic amines present in cigarette smoke. Women with a NAT2 slow
acetylator phenotype have increased breast cancer risk [42]. Slow acetylators increase the
exposure time to carcinogens, thus increasing susceptibility. The formation of DNA
adducts were more common in slow acetylators [43]. Thus, genetics has a role in
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cigarette smoke induced mammary carcinogenesis. This observation further proves that,
breast cancer is a complex disease and many factors contribute to an individual’s risk of
being diagnosed with it.
Environmental Pollutants
The two environmental pollutants most commonly associated with breast cancer
are polycyclic aromatic hydrocarbons (PAHs) and polychlorinated biphenyls (PCBs).
PAHs are genotoxic oxidants formed as a result of incomplete combustion and are found
in tobacco smoke, diet, and indoor and outdoor air pollution, [44]. PAHs have been
linked to breast cancer through several epidemiological studies [45-48] and have been
shown to cause mammary cancer in animal studies [39]. PAH DNA adducts can cause
DNA damage over the course of a few months to a year, depending on cell turnover rate
[45, 49]. In addition, PAHs are lipophilic and can be stored in adipose tissue for a long
time [47]. PCBs are found in lubricants, liquid sealants, flame retardants and electrical
insulators [50]. Despite curtailing the production and distribution of PCBs by the Toxic
Substances Control Act of 1976, PCBs remain persistent in certain environments due to
improper disposal, leakage from industrial products, and chemical spills [51]. PCBs are
classified as a group 1 carcinogen by the International Agency for Research on Cancer.
PCBs are also lipophilic and accumulate in adipose tissue. The dioxin-like (coplanar)
PCBs activate the aryl-hydrocarbon receptor (AhR) signal transduction pathway resulting
in altered gene expression promotion of tumorigenesis [52-55]. On the other hand, nonplanar PCB congeners induce oxidative stress, DNA damage and apoptosis in
mammalian cells [56-60].

5

Lifestyle
Many lifestyle choices can impact an individual’s risk to breast cancer. Not
having children or having the first child after the age of 30, not breastfeeding, long term
use of contraceptive pills, and the use of hormone replacement therapy increase risk to
breast cancer [61]. High physical activity has been shown to reduce breast cancer risk in
women, with an average of 20 to 25% reduction in breast cancer risk in women with a
higher level of physical activity compared to women with lower level of physical activity
[62-64]. In addition to physical activity, certain diet has been associated with improved
breast cancer risk and disease progression [65]. A review by Davies et al. suggested that
a diet high in fiber and low in fat might be protective against breast cancer progression
and recurrence [66]. Another study showed that eating a minimum of five fruit and
vegetable servings daily, while maintaining a physically active lifestyle, improved the 10
year survival rate of breast cancer patients [67]. The American Cancer Society suggests
that overweight and obese people reduce weight gain, adopt a physically active lifestyle,
have a diet rich in vegetables and fiber-rich food, and reduce fat intake to reduce chances
of developing breast cancer [68].
Estrogen
In 1991, Women’s Health Initiative (WHI) research initiated a 15 year study on
the beneficial effect of post-menopausal Hormone Replacement Therapy (HRT) on heart
disease, cancer and bone fracture. This study had to be stopped prematurely in 2002 due
to the increased incidence of breast cancer, stroke, and heart complications in the
estrogen alone and the combination estrogen/progesterone treatment groups [69]. The US
National Toxicology Program classified estrogens as carcinogens, the International
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Agency for Research on Cancer (IARC) also classified both estrogens and
estrogen/progesterone combined post-menopausal therapies as known carcinogens [70].
Epidemiological, animal, and in vitro studies indicate endogenous estrogens are involved
in breast carcinogenesis [71]. Evidence towards estrogen’s role in breast cancer started
with the observation that a double oophorectomy significantly reduces breast cancer risk
[72]. Breast cancer risk factors, such as early onset of menarche (12 years), late onset of
menopause (55 years), and having no children or having them late in life, are indicative
of a lifetime of mammary tissue exposure to sex hormones [71].
Many mechanistic studies have been conducted to understand the role of
estrogen-associated signal pathways in carcinogenesis. Estrogen increases c-Myc and
cyclin D1 expression inducing cell proliferation; whereas, antiestrogen agents have a
converse inhibitory effect [73]. Estrogen increases Bcl-2 and Bcl-XL expression in breast
cancer cells and inhibits apoptosis [74]. In breast cancer cells, estrogen stimulates
interleukin 8 and vascular endothelial growth factor secretion, both of which can
potentially induce angiogenesis. As opposed to this, antiestrogen tamoxifen decreases
tumor angiogenesis in ER+ breast cancer cells [75-77]. Research into the role of estrogen
in breast tumor formation has led to the development of several antiestrogens as the
primary breast cancer treatment given that two third of breast cancer is ER+. Surgical
oophorectomy was the method chosen to treat women diagnosed with premenopausal
breast cancer prior to the development of antiestrogens. The American Society Clinical
Oncology no longer recommend oophorectomy for the treatment of breast cancer due to
the success of antiestrogen drugs [78]. The first of these antiestrogen agents was
tamoxifen, which was introduced in the 1970s. It is the preferred choice of treatment due
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to its efficacy and low price. It is also used as adjuvant therapy to prevent breast cancer
recurrence in both pre and postmenopausal women [79]. The introduction of tamoxifen
was followed by the rapid development of selective estrogen modulators (SERMs) and
aromatase inhibitors (AI). SERMS, a group of compounds which are structurally similar
to estrogens, can bind to and modulate estrogen receptor (ER) function in different tissues
[80]. In addition to tamoxifen, the FDA has approved two other SERMs, toremifene and
raloxifene. Toremifene has antiestrogen activity in the mammary gland. It is used to treat
postmenopausal women with metastatic breast cancer. Raloxifene is a second generation
drug with a secondary use in osteoporosis prevention [81]. Fulvestrant is a third-line
treatment for postmenopausal women that have ER+ tumors. It modulates ER by
promoting ER turnover in cells [82, 83]. In addition to SERMs, another class of agents
for the treatment for breast cancer was developed based on the observation that breast
cancer tissue has higher levels of estrogen compared to non-cancerous cells. Aromatase
catalyzes the final rate limiting step of estrogen synthesis. AIs (e.g. anastrazole, letrozole
and exmestane) are used to treat breast cancer in postmenopausal women [84].
Epigenetics
Many studies have implicated epigenetic changes in breast cancer pathogenesis.
DNA methylation and post translational histone modification are the main epigenetic
modifications associated with breast cancer. Hypermethylation of promoter CpG islands
is one method of gene inactivation which could occur in the initial stages of breast cancer
development. In one study, 802 breast tumors were examined by the Cancer Genome
Atlas Network. This work resulted in identifying many genes that are differentially
methylated [85]. Many of these aberrantly methylated genes play critical roles in

8

apoptosis, cell cycle regulation, tumor suppression, angiogenesis, epithelial-mesenchymal
transition (EMT) and metastasis [86, 87]. Studies have also shown how methylation
changes can be an early sign of developing breast cancer and correlate with the
development of breast cancer [88]. Methylation of genes like GHSR can be used to
differentiate breast cancer from normal breast tissue [89]. Studies also suggest that higher
level of methylation is indicative of more aggressive metastatic breast cancer [90]. Hyper
methylation of pro-apoptotic gene (HOXA5, TMS1), cell cycle inhibitors (p16,
RASSF1A), and DNA repair genes (BRCA1) have been identified in metastatic breast
cancer cells [91]. Distinct patterns of posttranslational histone modification have been
observed

in

breast

cancer.

DNA

methyltransferases

(DNMTs)

and

histone

desacetyltransferase (HDAC) are highly expressed in the promoter of the ER gene,
inactivating ER in ER negative breast cancer [92, 93]. Histone modification leads to the
down regulation of E-cadherin which is necessary for the initiation of EMT [94].
Genetics
The genetic component of breast cancer development was first noted with the
observation that there is a higher prevalence of breast cancer in monozygotic twins of
patients compared to dizygotic twins or siblings of patient. The incidence is also high in
1st degree relatives of breast cancer patients. This risk is greater for individuals with more
affected relatives and is also greater if these relatives were diagnosed at a younger age
[95-98]. Approximately 5 to 10% of breast cancer cases are autosomal dominant,
following a Mendelian pattern of inheritance. Another 15 to 20% of breast cancer cases
are familial (women with first or second degree relatives that have the disease). Among
hereditary breast cancer cases, 30% are attributed to germline mutations in high
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penetrance alleles of BRCA1 and BRCA2 [3, 99]. Studies over the past two decades have
shown that the genetic component of breast cancer susceptibility is complex and
comprises of genetic variation at many different loci. These susceptibility alleles differ in
their population based frequency and the relative risk that they confer. The genetic
component of breast cancer susceptibility comprises of high penetrance alleles, moderate
penetrance alleles and low penetrance alleles. As shown in figure 1, high penetrance
alleles confer a greater than 50% of the lifetime risk of breast cancer, moderate
penetrance alleles confer a lifetime risk of 20% or more; whereas, low penetrance alleles
confers a lifetime risk of 10 to 20% [100].
High Penetrance Alleles
High penetrance alleles affect individuals, usually at a younger age and are
present in some families with a breast cancer history. Such families were subjected to
linkage analysis and positional cloning to identify high penetrance alleles in BRCA1 and
BRCA2, two tumor suppressors which are involved in DNA repair [101, 102]. These
genes are relatively rare in a given population, they have a cumulative frequency of 1 in
800 for BRCA1 mutations and 1 in 500 for BRCA2 mutations and they confer an 85% risk
by the age of 70 [103, 104]. Mutations in BRCA1 and BRCA2 are responsible for
approximately 84% of families with more than 3 members diagnosed with breast cancer
at younger than 60 years of age [103]. Other high penetrance alleles have been identified
by studying syndromes with inherited cancers as a symptom. TP53 mutations were
identified in Li-Fraumeni Syndrome and STK11/LKB1 mutations found in Peutz-Jegher
Syndrome

[105,
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106].

Figure 1. Genetic Architecture of Breast Cancer Susceptibility. Adapted from
Ghouussani et al (2013). Figure shows the relative risk associated with different risk
alleles as a plot against its respective allele frequency. Genes associated with breast
cancer

risk

are

further

classified

into

groups
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based

on

level

of

risk.

BRCA1 and BRCA2
In 1990, BRCA1 was the first major gene associated with hereditary breast cancer.
It is present on chromosome 17 and was identified by linkage analysis of individuals in
families with a history of breast cancer [107]. BRCA1 is involved in homologous
recombination to repair double stranded breaks in DNA [108]. BRCA1 is also involved in
cell cycle control, as an upregulation of BRCA1 results in upregulation of p21 and G1-S
cell cycle arrest [109]. In 1994, BRCA2 was associated with increased risk to breast
cancer in a genetic maping project focused on chromosome 13 [110]. Like BRCA1,
BRCA2 is also involved in DNA damage repair by homologous recombination [111].
Individuals with BRCA mutations are said to have Hereditary Breast/Ovarian Cancer
Syndrome (HBOC). BRCA1 related tumors tend to be ER, PR and Her2/neu negative
while BRCA2 related tumors are ER positive [112, 113]. BRCA mutations are inherited
in an autosomal dominant fashion, but act recessively to bring about a phenotype of
cancer. This is because loss of both copies is required, as these tumor suppressor genes
are involved in double stranded DNA break repair [114]. BRCA1 mutation carriers have a
10 to 40% lifetime risk whereas BRCA2 carriers have 10 to 20% lifetime risk of ovarian
cancer [115]. Inherited biallelic BRCA2 mutations result in a Fanconi anemia type D1
like phenotype while inherited biallelic mutations in BRCA1 are not documented, as this
condition is likely embryonic lethal [114]. Women with BRCA mutations should be
counseled regarding breast awareness and breast self-exam by 18 years of age. Annual
MRI checkup is usually recommended from 25 years of age. Risk-reducing salpingooopherectomy (RRSO) is recommended after the age of 35 based on family history and

12

reproductive history. Prophylactic mastectomy is also frequently considered due to high
lifetime risk and risk of secondary breast cancer [116-118].
Moderate Penetrance Alleles
Moderate penetrance alleles have been identified by resequencing genes that
interact with BRCA1 and BRCA2, or those which are a part of DNA repair pathways.
Variants of ATM, CHEK2, PALB2 and BRIP1 show a 2 to 4 fold increase in breast cancer
risk [119-123]. Linkage studies in families with rare syndromes that affect the breast, led
to the identification of PTEN and CDH1. PTEN and CDH1. All confer a relative risk of
two to eight [124, 125]. Altogether these genes account for less than 25% of risk
associated with familial breast cancer [126].
CHEK2
CHEK2*1100delC is the most common CHEK2 polymorphism, present in 1 to
2% of European population. This gene can have a prevalence as high as 5% in breast
cancer patients with a family history of breast cancer but BRCA1 or BRCA2 mutation
negative [121] . CHEK2 is involved in cell cycle regulation at the G2 phase. It is a kinase
that is phosphorylated in response to DNA damage. Activated CHEK2 interacts with
BRCA2 while stabilizing BRCA1 [127]. Individuals who are co-carriers of CHEK2
mutations and BRCA1 or BRCA2 mutations do not have an additional increase in risk as
they induce overlapping effects on DNA repair [121]. As with BRCA1 there is no known
biallelic phenotype for CHEK2, indicating this condition may be embryonic lethal [114].
BRIP1
BRIP1 (BACH1) mutations account for less than 1% of breast cancer cases.
Individuals with a history of breast cancer with BRIP mutations have a 2.0 relative risk of
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developing breast cancer. These individuals have a higher risk for the early onset of
breast cancer. BRIP1 interacts with BRCA1 C-Terminius (BRCT) domain of BRCA1.
Most of the mutations identified are protein truncating. Individuals that are biallelic for
BRIP1 mutations are associated with Fanconi anemia type J; these patients do not have a
significant increase in cancer during their childhood [119].
Low Penetrance Alleles
Low-penetrance breast cancer risk-associated alleles are fairly common in the
population, many having a minor allele frequency of greater than 5% and each attributing
to a small change in an individual’s risk to breast cancer (relative risk of less than 1.5).
Low penetrance alleles in the past have been identified in the past by case-control
association studies, where candidate genes based on their known function are studied
[128, 129]. This method is biased and may miss out on genes that are not yet functionally
characterized. Since the advent of better genotyping technology, genome wide
association studies (GWAS) have become possible. GWAS have led to the identification
of over 70 breast cancer susceptibility loci. These loci however only explain 14% of
familial breast cancer [100]. There is also some evidence that relative risk of low
penetrance alleles are modified by environmental risk factors like life style and
reproductive history [130]. Thus, there are many low penetrance alleles that remain to be
identified.
Rs889312
5q11.2 SNP (rs889312) was one of the SNPS identified in a GWAS to associate
with breast cancer susceptibility in a population with European ancestry [131]. The minor
allele for rs889312 was found to associate with a per allele odds ratio of 1.12 (95% CI =
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1.10 – 1.15, ptrend = 1.8x10-26) in the most recent Breast Cancer Association Consortium
(BCAC) [132]. The association was strongest for ER+ disease (OR = 1.14, 95% CI =
1.11 – 1.17, p = 1.1x10-26), but was also seen for ER- (OR = 1.06, 95% CI = 1.03 – 1.10,
p = 0.0024) and triple negative disease (OR = 1.11, 95% CI = 1.02 – 1.20, p = 0.016)
[133]. Carriers with BRCA2 mutations associated with a greater risk of developing breast
cancer if they carried the minor allele of SNP rs889312 [134]. Rs889312 is located in a
disequilibrium block (LD block) which contains three genes, MAP3K1, STED9 and
MIER3. MAP3K1 was considered as the candidate gene due to its driver mutations
observed in Luminal A and Luminal B breast tumors and other breast tumor sub types
[135, 136]. However, the study was not conclusive; and thus, any of the three genes or
combination thereof within the LD block and any of the SNPs that are in linkage
disequilibrium with rs889312 could be the gene(s) or SNP(s) causing breast cancer
susceptibility. Rats do not express a transcript of this gene [137]. MIER3, however, is
more highly expressed in breast tumors compared to normal breast tissue, making it a
candidate gene for a potential role in mammary carcinogenesis [137] This genomic
region needs to be studied further to understand its role in female breast and rat
mammary carcinogenesis.
Animal Models of Breast Cancer
There is no perfect experimental model to study breast cancer, but knowledge
obtained from various models helps us to better understand this disease. Cell cultures are
the simplest and most practical model to use. However, it is an oversimplified model and
does not represent a complex in vivo tumor environment. Animal models come close in
representing the multi-organ complexity of breast cancer. It is important to remember that
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breast cancer represents an array of diseases and different experimental models are
needed to represent and study different aspects of this array of diseases.
Breast Cancer Cell Lines
Breast cancer cell (BCC) lines used in vitro and in vivo studies have contributed
significantly to the current knowledge regarding breast cancer. BCC lines, like any other
model, have advantages and disadvantages. One of the main advantages is that it provides
a homogenous, self-replicating model which can easily and quickly be cultured in simple
growth media. BCC lines have been studied for more than 5 decades with the first cell
line BT-20 described in 1958 [138]. Most BCC lines were established in the 1970s. A
select few of them, namely, MCF-7, T-47D, MDA-MB-231 account for a majority of the
research published [139]. Despite their role in understanding breast cancer, there are a lot
of concerns regarding BCC lines being a representative model. It is usually the study of a
single cell line which does not replicate or represent complex environments presented by
the milieu of cells and interstitial fluid present in breast tissue or tumor environments.
BCC lines are genetically unstable and long, stressful culture conditions can lead to its
genotypic and phenotypic alteration. These changes lead to discrepancies in data
interpretation and difficulties in replicating results [140]. One way of overcoming these
short comings is by using an animal model to study breast cancer.
Canine Models
Mammary cancer is the second most common cancer in dogs. It is the most
frequently diagnosed tumor in female dogs accounting for 52% of tumors diagnosed
[140]. Canine mammary cancer is similar to human breast cancer with respect to tumor
establishment and metastatic progression [141]. Canine mammary tumor like human
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breast tumors are hormone dependent [142]. There is a significant overlap between
canine and human genes that are deregulated in mammary cancer. Studies have shown
that the deregulation of BRCA1 and BRCA2 are associated with mammary tumor
development in dogs [143]. In another study, gene expression profiles from both human
breast and dog mammary tumors were compared to normal breast and mammary tissue
from the respective species. This study showed that in both species, similar pathways,
related to increase in proliferation activity, were upregulated; whereas, similar pathways
related to cell development, cell communication and cell matrix adhesion were down
regulated. Cancer-related pathways like phosphatidylinositol 3-kinase (PI3K)/AKT
pathway, KRAS, phosphatase and tensin homolog (PTEN), Wnt-b-catenin, and mitogenactivated protein kinase (MAPK) cascade were altered in both human and canine tumors
[143]. The close similarities between canine and human mammary cancer makes dogs an
appealing model to study human breast cancer. However, the disadvantages to using a
canine model include its large body size, higher cost of housing, longer life span and
fewer genetic tools available for manipulation as compared to its smaller, more easily
housed rodent counterparts, which have a shorter life span.
Mouse Models
The mouse is an extremely popular model to study human breast cancer. The
biology of mouse mammary gland has been studied and well characterized over many
years with respect to normal development, changes occurring during lactation and
developing spontaneous tumors. The popularity of the mouse as a model arises from its
short lifespan, small size, feasible housing cost, ease of breeding in captivity and a welldefined genome [144].
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Mice have been an extremely useful as xenograft and genetically engineered
(GEM) models to study breast cancer. Several mammary specific gene promoters have
been characterized enabling mammary specific engineering of genes. Several approaches
have been used to genetically engineer mice [145]. One of the approaches is to create a
transgenic (TG) mouse. Here, the gene of interest, like C-myc or Ras is randomly inserted
into the germline by directly injecting DNA into one of the two pronuclei of a fertilized
egg [146]. These mice have specific oncogene expression, usually controlled by
mammary gland specific promoters. TG mice provide the option of testing human genes
implicated in breast cancer in an in vivo setting [147]. Another mouse model which has
been very beneficial to the study of breast cancer is the human to mouse xenograft model.
Here, human cancer cells are grafted into the mouse resulting in a tumor with human
cancer cells within the murine stromal cells [148]. Another approach, preferred to study
tumor suppressor genes, like BRCA1 and BRCA2, involves the generation of knock out
mice. A nonfunctional version of the gene of interest is introduced into mouse embryonic
stem (ES) cells. Cells with the targeted “knockout” gene, integrated by homologous
recombination at the homologous site are selected. The resulting ES cells are used to
generate the desired knock out mouse. A disadvantage of this model is that it is not an
accurate representation of gene expression as most tumor-associated mutations are
somatic and are only present in tumor cells and not globally expressed. Another
disadvantage of this approach is that global inactivation of some genes often lead to
embryonic lethality. This shortcoming led to the development of the next approach to be
described where genes can be modified in the germline, but inactivated in a tissue
specific and time specific manner. The most established method for tissue specific
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knockout uses the Cre/Lox recombinase system [149]. LoxP are 34bp long genetic
elements which are recognized by Cre recombinase enzyme. Knock in mice with two Lox
sites on either end of the gene of interest are generated. These mice are still functionally
normal despite the Lox elements. The knock in mice are then crossed with transgenic
mice expressing Cre recombinase, which is controlled by tissue specific promoter, Cre
mediated recombination occurs, resulting in tissue specific knock out of the gene of
interest.
Despite its many advantages, a mouse model of breast cancer has its limitations.
They do not best represent human tumors with respect to, growth over long periods of
time, the role the immune system plays, and the heterogeneity observed in tumor cell,
microenvironment and stroma [150, 151]. Another limitation observed is that mouse
models are not predictive of tumor development in human tumors with the same
histology [152]. Biologic differences, such as functionally active telomerase in murine
cells unlike human cells, could affect oncogenesis [153, 154]. A majority of human breast
tumors are estrogen responsive, while mouse mammary tumors are generally estrogen
independent. Also, in most murine models, metastases occur hematogenously, and the
primary site of metastasis is the lung. In humans, breast cancer is characterized by
lymphatic and nodal metastases in addition to hematogenous metastases and sites of
metastasis include lung, liver, bone, and brain [155].
Rat Models
Rats are another popular rodent model used to study breast cancer. Rat mammary
cancer is very similar to human breast cancer with respect to histopathology, cell type of
origin, and hormone responsiveness. The histologic features of malignant tumors in rats
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are similar to intraductal and infiltrating ductal carcinomas in humans. Also,
fibroadenomas (FA) and adenomas are similar in rats and humans [156, 157]. In rat
mammary cancer, it was found that initiation of carcinogenesis occurs in the epithelium
of terminal end buds (TEBs) while they are developing into alveolar buds (ABs) and
terminal ducts (TDs). The TEBs in rat mammary glands are considered to be equivalent
to the terminal ductal lobular unit (TDLU) in the human breast [156, 158]. Preexisting
FA undergo rapid growth during pregnancy suggesting estrogen responsiveness. This
pattern of rapid growth of ducts, cells lining ducts amount of periductal fibrous tissue
found in FA is observed when both rat and human mammary glands are treated with high
doses of estrogen[159].
Rat Models and Chemical Carcinogens
In

addition

to

hormones,

chemical

carcinogens,

like

7,12-

dimethylbenz[a]anthracene (DMBA) and N-Nitroso-N-methylurea (NMU), have been
used experimentally to induce mammary cancer in rats. DMBA is usually administered as
a single dose of 2.5 – 20 mg by oral gavage. DMBA needs to be bioactivated to induce
carcinogenesis. NMU is also administered as a single dose of 25 – 50 mg/kg body weight
by intravenous, intraperitoneal, or subcutaneous injections. Both carcinogens usually
induce 100% tumorigenesis by 8-21 weeks [160]. Tumor number, latency and incidence
are a function of carcinogen dose administered. [161]. DMBA or NMU induced
carcinogenesis is age dependent and optimal at the age of sexual maturity which is 45 to
60 days of age in rats. Sexual maturity is marked by active organogenesis and glandular
epithelial proliferation [162-165].
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DMBA Induced Rat Mammary Carcinogenesis
In 1961, DMBA was reported to be a very specific and efficacious carcinogen to
induce mammary carcinogenesis in female rats [166]. DMBA induced mammary
carcinogenesis is dependent on the strain of the rat, age at DMBA administration,
topographic location of the mammary gland and reproductive history [166, 167]. DMBA
is a preferred carcinogen because it reliably induces mammary tumors and provides organ
specificity; further, mammary tumors generated are of ductal origin and hormone
responsive [168]. However, one limitation in the use of DMBA is that mammary
carcinomas induced by DMBA do not metastasize [169]. DMBA rat model has provided
several insights on the mode of carcinogenesis. DMBA induced carcinogenesis acts on
the intermediate cells of the terminal end buds (TEB) resulting in intraductal
proliferations and carcinoma in situ [156]. This provides an excellent model to study and
identify mechanisms of breast cancer progression.
DMBA and Mammary Cancer Associated Quantitative Trait Loci (QTL) in the Rat
Genome
Different strains of rats vary in their susceptibility to DMBA induced mammary
cancer. This difference in susceptibility is not due to a difference in the ability of these
strains to metabolize DMBA [170]. Studies have shown a genetic basis for the observed
differential susceptibility to DMBA induced mammary carcinogenesis. The Wistar-Furth
(WF) rat is highly susceptible while the Copenhagen (Cop) rat and Wistar-Kyoto (WKy)
rats are highly resistant to DMBA induced mammary carcinogenesis [171]. Genetic
linkage analysis performed on (WF × Cop) F1 × WF backcross (BC1) rats using tumor
number post-DMBA administration as the phenotype. Microsatellite markers were used
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to determine the genotype of rats that were phenotyped. This led to the identification of
mammary carcinoma susceptibility locus 1 (Mcs1) on rat chromosome 2 as a locus that
reduces mammary carcinoma susceptibility [172]. In an extension to this study, BC1 rats
were further studied along with a linkage analysis performed on a panel of BC1 × BC1
backcross (BC2) rats and F2 (F1 × F1) rats to identify Mcs2, Mcs3, and Mcs4 on rat
chromosome 7, 1 and 8 respectively. Mcs1, Mcs2, and Mcs3 loci reduce susceptibility of
the susceptible strain, while Mcs4 increases DMBA induced mammary carcinoma
susceptibility [173]. A similar linkage analysis, performed using the susceptible WF rat
and resistant WKy rat, led to the identification of Mcs5, Mcs6, Mcs7, and Mcs8 on rat
chromosome 5, 7, 10 and 14, respectively. Mcs5, Mcs6 and Mcs8 are associated with
decreased susceptibility, while Mcs7 is associated with increased susceptibility to DMBA
induced mammary carcinogenesis compared to the susceptible strain phenotype [174].
All loci except Mcs3 and Mcs7 have been studied beyond the initial mapping studies.
To study the Mcs loci congenic rats were generated using the scheme displayed in
figure 2. These congenic rats contain only the Cop or WKy allele of interest on a
completely WF genetic background. To generate congenic rats, homozygous rats of the
parent strains are bred to generate heterozygous F1 rats (Cop × WF or Wky × WF). The
F1 rats are backcrossed with the susceptible WF parent to generate N2 rats. These rats are
then successively backcrossed with the susceptible WF parent by selecting carrier rats
with Cop or WKy allele of interest at each generation. Microsatellite markers and/or
single nucleotide variants are used to genotype these rats to select carrier rats with the
genotype of interest. The carriers are backcrossed for up to ten generations at which point
the congenic rats usually only carry the Cop or WKy allele of interest on a completely
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susceptible WF genetic background. These congenic rats are then used to study the Mcs
locus of interest.
So far, Mcs5 is one of the most studied Mcs locus. Mcs5 was initially predicted as
a locus that reduces mammary carcinoma susceptibility based on genetic linkage analysis
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Figure 2. Generation of Congenic Lines. Susceptible rat strain is crossed with a
resistant rat strain. The F1 generation is backcrossed with the susceptible parent strain,
and subsequent offspring are backcrossed to the susceptible strain for ten generation by
selecting for rats with the desired genotype. By the tenth backcross, the congenic rat with
desired allele from the resistant rat strain, present on a completely susceptible genetic
background is generated. The red and green bars represent the DNA from the different
parent rat strains. The green bars indicate DNA from the susceptible rat strain and the red
bars indicate DNA from the resistant rat strain.
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performed on WKy and WF rats and was later physically confirmed as independently
acting locus on rat chromosome 5 [174, 175]. Fine mapping this locus led to the
identification of Mcs5a, Mcs5b, and Mcs5c loci. Mcs5a and Mcs5c reduce mammary
carcinoma susceptibility while Mcs5b increases mammary carcinoma susceptibility in
WF.WKy congenic rats compared to WF rats [176]. Studying each allele of these loci
showed that neither the WF nor the WKy Mcs5a allele is dominant. Mcs5a and Mcs5b
have an epistatic interaction where the Mcs5a allele masks the increased susceptibility of
the Mcs5b allele. Mcs5a and Mcs5c interact synergistically to reduce mammary
carcinoma susceptibility below the additive effect of the Mcs5 alleles at each locus
independently [176].
Fine mapping the Mcs5a locus showed that it contained 2 genetic elements,
Mcs5a1 and Mcs5a2. Thus, Mcs5a is a compound locus and is functional only when the
Wky allele Mcs5a1 and Mcs5a2 are in cis confirmation on the same chromosome.
Mcs5a1 is located within Fbxo10 and the Mcs5a2 includes the 5’ region of Frmpd1.
Fbxo10 was differentially expressed in thymus and Frmpd1 was differentially expressed
in the thymus of congenic rats compared to the WF control rats. Also, a study of the
orthologous region in humans identified MCS5A1 and MCS5A2 as alleles with high
population based risk and low population frequency [177]. Mcs5a Wky allele is
associated with γδTCR+ T-cells proliferation and cytokine production in mammary
epithelium exposed to carcinogens [178]. Mcs5a modulates mammary carcinoma
susceptibility by a chromatin looping mechanism to down regulate Fbxo10 expression in
T cells in both humans and rats [179]. In a recent study it was found that c-Fos binds
AP1- specific DNA elements in Mcs5a1, thereby regulating FBXO10/Fbxo10 expression
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by a PKC-dependent pathway [180]. Mcs5a is a prime example of how the rat has been
used as a model to study the mechanism of human breast cancer susceptibility.
Mcs3
The work presented in this dissertation will focus on two different mammary
carcinoma susceptibility loci, Mcs3 and Mcs1b. In contrast to the Mcs5 locus, which is
well characterized, little is known about genetic variants associated with Mcs3 and its
underlying mechanism. Mcs3 is a locus predicted on chromosome 1 across two peak
markers D1Mit11 and D1Wox6 as shown in figure 3. Mcs3 was predicted in a genetic
linkage analysis using the WF and Cop rats. The Mcs3 Cop allele was predicted to
associate with reduced tumor number as compared to its WF allele [173]. Since, the Mcs3
locus is predicted at two peak markers, which are 29Mb apart, its exact physical location
and architecture may be complex. It may be a complex locus due to additive [181],
dominant, epistatic, and synthetic [177] effects of low penetrance genes. The mechanism
of action of a predicted locus and its complexity can be better identified by mapping the
locus to as small a chromosomal region as possible. Also, for human studies it is
convenient to map to a region of shared synteny. Thus, both physical confirmation and
positional mapping of this region are necessary.
Mcs1b
The second part of this dissertation focuses on the Mcs1b locus. Mcs1 rats
developed an average of 1.2 tumors per rat post DMBA administration which was
significantly lower than the WF rats which developed an average of 8.5 tumors per rat.
Mcs1 was confirmed as a locus that reduces mammary carcinoma susceptibility [172]. To
analyze the complexity of the Mcs1 locus, different recombinant congenic lines
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Figure 3. Representation of Predicted Mcs3 Locus. Figure represents the Mcs3 locus
which is predicted on rat Chromosome 1 across two peak markers D1Mit11 and D1Wox6.
The X-axis indicated the position on rat chromosome 1 and the Y-axis represents the
LOD score.
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with varying lengths of the Cop allele at the Mcs1 locus were generated and phenotyped.
This led to the identification of Mcs1a, Mcs1b, and Mcs1c loci, all of which reduce
susceptibility to mammary carcinogenesis. [181]. Mammary gland grafting assays later
showed that the Mcs1b locus acts in a mammary gland autonomous manner. The Mcs1b
locus is of particular interest since it is orthologous to a GWAS identified locus
associated with increased breast cancer incidence [131]. Haag et al. initially defined the
Mcs1b locus between markers D2Uwm17

proximally and

D2Rat16 distally

(~13cM/11Mb) [181]. Recent work in our lab has delineated the Mcs1b locus to a 1.8 Mb
region of rat chromosome 2 which is represented by congenic line N3 in figure 4 [137].
Mcs1b heterozygous congenic rats tested by Haag et al. developed an average of 7.6
tumors/rat [181]; whereas Mcs1b heterozygous congenic rats tested by denDekker et al.
developed around 5.5 tumors/rat [137]. This discrepancy in tumors developed by rats that
are heterozygous Cop at the 1b-11 locus observed in two different studies could be
indicative of a complex genetic interaction within the Mcs1b locus. To continue finemapping Mcs1b, it is essential to generate recombinant congenic rats with smaller regions
of the Mcs1b locus. Backcrossing line T (figure 4) generated the congenic line 1b-11
which spans the distal end of the Mcs1b locus. A preliminary number of 1b-11 rats have
been phenotyped, but more 1b-11 (figure 4) rats need to be phenotyped to determine the
effect of Cop 1b-11 allele on susceptibility to DMBA-induced mammary carcinogenesis.
Results from the same study by denDekker et al. that reported Mcs1b acts in a
mammary gland cell autonomous manner, suggest that Mcs1b is a non-protein coding
genetic element [137]. Mcs1b associated phenotypes include altered expression levels of
Map3k1, Il6st, Gpbp1 and mesoderm induction early response1, family member3 (Mier3)
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Figure 4. WF.Cop Congenic Map that Defines the Mcs1b Locus. Figure represents
varying segments on rat chromosome 2 where Mcs1b was predicted to be located and
congenic lines that were used to fine-map this locus. On the X axis, blue lines represent
informative microsatellite markers, red lines represent informative SNPs, and green lines
represent informative indels. Brown bars represent Cop alleles in congenic lines with a
resistant phenotype, yellow bars represent congenic lines with a susceptible phenotype,
white bars represent congenic lines with an unknown phenotype and grey bars represent a
potential area of recombination where the genotype isn’t determined. The horizontal blue
bar represents the orthologous region to human 5q11.2 breast cancer risk (BRCR)
associated haplotype block.
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in mammary glands. Of all the genes contained within the Mcs1b region only Mier3 was
differentially expressed between the mammary glands of Mcs1b resistant and susceptible
WF rats with or without DMBA administration. Mier3 expression was 4.5 fold lower in
mammary glands of the resistant congenic rats compared to susceptible WF rats [137].
These differential expression patterns were not observed in corresponding spleen,
thymus, ovary or brain tissues; therefore, Mier3 transcript levels vary specifically
between susceptibility genotypes in mammary gland tissue. It was also found that Mier3
transcript level was 1.8 times higher in mammary carcinomas as compared to
surrounding disease-free mammary tissue; human MIER3 levels were respectively 1.33
and 1.20 times higher in invasive ductal and invasive lobular carcinoma samples
compared to normal breast tissue [137, 182]. Thus, MIER3 is a potential candidate breast
cancer susceptibility gene. MIER3 is an uncharacterized gene with a protein product
localized to the nucleus [137]. Immunohistochemistry staining for Mier3 in mammary
gland tissue of congenic rats showed that it is not uniformly expressed in all cell types but
is specific to a sub-population of epithelial cells lining the duct (figure 5). It was also
identified that an alternative 5’ transcriptional start site variant of Mier3 is differentially
expressed between Mcs1b congenic and WF rat mammary glands compared to other
Mier3 variants [137]. Differentially expressed 5’ start variants are typically indicative of
cell or tissue type specific expression. Hence, it is possible that Mier3 is either
responsible for reduced susceptibility to mammary carcinomas conferred by Mcs1b, or it
is a marker of a specific cell type in the mammary gland that is responsible for this
phenotype.
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Figure 5. Expression of Rat Mier3 in Cells Lining Mammary Ducts. Figure displays
IHC staining for Mier3 as compared to IgG in transverse sections of rat mammary gland.
Red arrows point to a rat mammary duct. The first panel shows an H&E stained section
to observer the general layout of the tissue, the second panel shows the same section IHC
stained for IgG, and the third panel shows this IHC stained section for Mier3.
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Overall Goals
This goal of this dissertation work is two fold. The first goal will be to confirm
the existence of predicted mammary carcinoma susceptibility QTL on RN01 named
Mcs3. If confirmed, this can potentially lead to the discovery of new mammary
carcinoma susceptibility modifiers and related mechanisms. The second goal of this
dissertation work will be to further characterize the Mcs1b locus. The Mcs1b locus can be
delineated to a shorter region on chromosome 2 or a complex interaction in this region
may be identified; either of these results will help identify susceptibility modifier
mechanism. Mier3 is either an ortholog of a candidate breast cancer susceptibility gene or
a potential marker of a cell or tissue type that contributes to or explains altered mammary
carcinoma susceptibility. Experiments proposed will help identify which of these roles
Mier3 plays in mammary carcinoma susceptibility.
Hypotheses
Hypotheses 1
Mcs3 QTL is an independently acting mammary carcinoma susceptibility locus on
RN01. Mcs3 may have at least two independently acting sub-loci corresponding to two
peak linkage analysis markers within this region.
Hypotheses 2
Mcs1b is a complex locus which alters DMBA-induced mammary carcinoma
susceptibility. Congenic line 1b-11 contains a genetic element/s responsible for the
Mcs1b associated phenotypes.
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Hypotheses 3
Differential mammary gland expression levels of Mier3 between Mcs1b line N3
and susceptible WF females are due to a difference in MEC numbers between mammary
glands of WF and Mcs1b congenic rats.
Specific Aims
These hypotheses will be tested by the following aims:
Specific Aim 1
Physically confirm predicted mammary carcinoma susceptibility QTL on RN01
named Mcs3 using WF.Cop congenic rats. I will simultaneously determine if, Mcs3 is
defined by two independently acting sub-loci.
Specific Aim 2
To determine if the WF.Cop line 1b-11 allele alters Mcs1b associated phenotypes.
Specific Aim 3
To determine if Mier3 is differentially expressed due to mammary epithelial cell
population differences between congenic N3 and WF rats.
To determine if Mier3 levels are lower in mammary gland tissue of Mcs1b rats
due to genotype associated differences in mammary gland epithelial cell numbers.
To determine if Mier3 is differentially expressed in mammary gland tissue of
Mcs1b-resistant and Mcs1b -susceptible rats due to a difference in Mier3 expression
levels

in

a

population

enriched

for
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CHAPTER II
MAMMARY CARCINOMA SUSCEPTIBILITY LOCUS, MCS3:
PHYSICAL CONFIRMATION AND COMPARATIVE GENOMICS
Introduction
According to cancer statistics for 2016, breast cancer will be the most commonly
diagnosed cancer among women, accounting for 29% of cancers diagnosed and 14% of
cancer related deaths in women. Women have a population-based estimated 1 in 8 chance
of being diagnosed with breast cancer in their lifetime [1]. It is a complex disease
controlled by genetic, epigenetic and environmental factors. The genetic component of
breast cancer susceptibility is comprised of high to low penetrance risk alleles [183].
Linkage analysis and genome-wide association studies have enabled the identification of
several of these alleles, but a majority of these alleles remain to be identified [99, 184186]. Emerging research is currently focusing on breast cancer not as a single disease, but
as an array of diseases associated with varying mechanisms. Different approaches (e.g.
cell culture studies, animal model based studies, and genome wide association studies)
are being used to study breast cancer, each with its own advantages and disadvantages
[157, 187, 188].
Technology has advanced leaps and bounds and sequencing costs have declined
considerably making genome wide association studies (GWAS) a very popular method to
address genetic variations associated with breast cancer. However, like any method,
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GWAS have its limitations and drawbacks. One of the basic problems is identifying
spurious associations caused due to confounding effects of environment and/or genetic
background [189]. Another problem associated with GWAS is the use and comparison of
heterogeneous populations. This not only leads to spurious associations, but also hinders
the identification of single nucleotide variants (SNVs) with smaller effect sizes [190].
Associated risk alleles identified with GWAS may nominate candidate genes, but
identifying the causal genes requires fine mapping and, molecular and mechanistic
studies. These studies become especially challenging if the SNVs detected fall in gene
deserts [191, 192]. One way these shortcomings of GWAS might be overcome is by
studying breast cancer risk alleles using experimental organisms. Rats vary in
susceptibility to mammary carcinogenesis. These rat models help identify loci associated
with breast cancer which can be tested in human populations to identify SNVs associated
with breast cancer risk [193]. The added advantage of using rats is that it offers an
experimental model to study genetically determined mechanisms associated with breast
cancer [194].
Inbred rat strains that differ in susceptibility to 7,12-Dimethylbenz[a]anthracene
(DMBA) induced carcinogenesis have been used to identify mammary carcinoma
susceptibility (Mcs) loci by linkage analysis [172, 173]. Rats are a good model of human
breast cancer, as rat mammary carcinomas are similar to human breast carcinomas with
respect to histopathology [195]. The cell of origin of both rat mammary and human breast
carcinomas is mammary ductal cells [196]. Rat mammary carcinomas are also similar to
human breast cancers with respect to hormone responsiveness; this is opposed to mouse
mammary carcinomas, which are usually refractive to hormones [195]. Linkage analysis
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using the DMBA sensitive Wistar-Furth (WF) strain and DMBA resistant Copenhagen
(Cop) strain led to the prediction of four Mcs loci (i.e. Mcs1, Mcs2, Mcs3, and Mcs4)
[172, 173]. In this study, we focused on Mcs3, a predicted Mcs QTL, with two peak
markers, D1Mit11 and D1Wox6, present on rat chromosome 1 [173]. We have physically
confirmed Mcs3 and mapped this QTL to a 25.8 MB region on rat chromosome 1.
Results
Physical Confirmation and Fine Mapping Mcs3 Using WF.Cop Congenic Rats
Figure 6 is a congenic map of WF.Cop congenic lines that were used to physically
confirm and map the location of rat Mcs3 QTL that was predicted by Gould and
colleagues to exist on rat chromosome 1 [181]. Table 1 contains the DMBA induced
mammary carcinoma susceptibility phenotypes (mean ± SD mammary tumor number per
rat) of the congenic lines depicted in Figure 6. The WF.Cop congenic lines A and D
developed 3.4 ± 2.2 and 2.8 ± 2.3 DMBA-tumors/rat, respectively. A combined group of
susceptible WF females and WF/WF homozygous genotype littermates from congenic
lines developed 6.3 ± 3.9 DMBA-induced tumors per rat. The susceptible WF phenotype
in this study was similar to results previously published by denDekker et al where
susceptible control WF rats developed 6.3 ± 3.3 tumors per rat upon DMBA induction
[197]. Lines A and D rats developed significantly less mammary tumors per rat compared
to the susceptible WF females (Mann-Whitney test post hoc p-values = 0.0208 and
0.0167, respectively). Reduced susceptibility lines A and D were not different from each
other with respect to DMBA induced tumor multiplicity (Mann-Whitney test post hoc pvalues = 0.496). Thus, the reduced susceptibility phenotypes of lines A and D physically
confirmed

the

Mcs3

37

locus.

Figure 6. WF.Cop Congenic Map that Defines the Mcs3 Locus. Figure represents
varying segments on rat chromosome 1 where Mcs3 was predicted to be located and
congenic lines that were used to map this locus. On the axis, horizontal lines represent
informative markers that were used to distinguish the WF genotype from the Cop
genotype. Superscript letters indicate which line the respective line was derived from.
Red bars represent Cop alleles in congenic lines with a resistant phenotype, yellow bars
represent congenic lines with a susceptible phenotype, and grey bars represent segments
of

unknown

recombination

where

the
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genotype

wasn’t

determined.

Table 1. Summary of Mammary Carcinoma Susceptibility Phenotype of WF.Cop
Congenic Lines Used to Map the Mcs3 Locus
WF.Cop congenic lines
A

D

E

G

WF/NHsd

ENSRNOSNP2783780/

D1Rat320

ENSRNOSNP2783780/

D1Mit30/

-

ENSRNOSNP2784322

/ D1Rat65

ENSRNOSNP2784133

D1Rat321

3.4 (2.2)

2.8 (2.3)

6.6 (3.4)

8.1 (3.4)

6.3 (3.9)

N

30

19

25

29

12

p-value 2

0.010

0.008

0.467

0.496

Congenic

region

1

(marker/marker)
Mean (SD) Mammary
Carcinomas per Rat

1

Informative markers that identified the length of the Cop Chr1 segment

introgressed onto a susceptible WF genetic background.
2

p-values are obtained by performing Mann-Whitney nonparametric post hoc tests

and comparing each phenotype to control WF phenotype after a statistically significant
Kruskal-Wallis test of p-value  0.0125.
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Congenic lines E and G developed 6.6 ± 3.4 and 8.1 ± 3.4 mammary tumors per
rat, respectively. Lines E and G did not differ in tumor multiplicity compared to
susceptible WF rats (Mann-Whitney test post hoc p-values = 0.467677 and 0.496
respectively). Lines E and G phenotypes were not different when compared with each
other (Mann-Whitney test post hoc p-values = 0.496). The congenic segment overlap
between lines that contain at least one independently acting allele (A and D), and the
overlap and non-overlap of these lines with congenic line segments that do not contain
independently acting alleles (E and G) can be used to delimit QTL intervals. Congenic
Mcs3-asscociated reduced-susceptibility lines A and D overlapped each other minimally
from markers D1Rat321 to ENSRNOSNP2784267, and maximally from D1Rat 320 to
ENSRNOSNP2784322 (Figure 6). Susceptible line E overlapped lines A and D from
ENSRNOSNP2783800 to ENSRNOSNP2784088. Susceptible Line G overlapped
susceptible line A. These results indicated that the region between ENSRNOSNP2783800
and ENSRNOSNP2784088 does not contain an independently acting Mcs QTL. Taken
together, our congenic studies here indicated lines A, D, E and G delimited the Mcs3
QTL to a 25.8 Mb region on rat chromosome 1 that spans from ENSRNOSNP2784088 to
ENSRNOSNP2784322 (~25.8 Mb, 138,096,182 – 163,886,079).
Human Ortholog to Rat Mcs3 Locus
The Mcs3 locus from ENSRNOSNP2784088 to ENSRNOSNP2784322 was found
to align to four syntenic regions that are on human chromosomes 11 and 15 as shown in
table 2. Figure 7 contains known genes at the Mcs3 locus. These genes were identified
using the November 2004 rat assembly (build 3.4/rn4) at the UCSC Genome Browser.
The
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Figure 7. Transcript Map of the Defined Mcs3 Locus. Map shows known and
predicted transcripts within the defined Mcs3 locus that were annotated on the UCSC
Rattus norvegicus version 3.4/rn4 Genome Browser. The X axis represents the Mcs3
locus which is present on rat chromosome 1 from genetic makers D1 Rat350 to D1
Rat277. The marker position is represented by labeled tick marks on the X-axis. The
vertical lines demarcate the maximal Mcs3 locus. The transcripts are shown by their
NCBI gene symbols at their approximate genomic positions.
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Table 2. Loci on Human Chromosome That are Syntenic to the Rat Mcs3 Locus on
Chromosome 1 from ENSRNOSNP2784088 to ENSRNOSNP2784322.
Information regarding human loci that are Orthologous to Rat Mcs3 locus
(Chromosome 1: 138,096,182 – 163,886,079)
Human chromosome: base

Percent identity

Percent identity

position

between bases (%)

between span (%)

11: 71,626,810 –89,350,902

25.3

63.3

11: 3,631,069 –6,744,074

2.9

15.7

15: 80,282,370 –82,577,745

3.6

8.2

15: 83,803,297 –84,806,774

1.3

3.4

Position is Rattus norvegicus genome build version 3.4.
Position is Homo sapiens genome build version hg19.
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Table 3. List of Genes and Genomic Position in the Rat Mcs3 Locus and in the
Orthologous Human Region Obtained Using Ensembl Genome Browser

Rattus norvegicus
Genes
Location
Hdgfrp3 (ENSRNOG00000019740)
1:138098819-138119696
D4A0X9_RAT (ENSRNOG00000019770)
1:138189345-138202803
Sh3gl3 (ENSRNOG00000019776)
1:138398334-138529056
F1M767_RAT (ENSRNOG00000010840)
1:138563870-138876886
Fam154b (ENSRNOG00000026296)
1:138905988-138920522
Eftud1 (ENSRNOG00000032723)
1:138920620-139014913
D3ZFL6_RAT (ENSRNOG00000025142)
1:139135884-139138449
D4ABU9_RAT (ENSRNOG00000036972)
1:139418553-139442493
Tmc3 (ENSRNOG00000025088)
1:139842574-139886756
Stard5 (ENSRNOG00000025052)
1:139896272-139905625
Il16 (ENSRNOG00000011680)
1:139908061-140000146
RGD1310371 (ENSRNOG00000012301)
1:140036328-140061890
Mesdc1 (ENSRNOG00000012349)
1:140157974-140159062
Mesdc2 (ENSRNOG00000012366)
1:140167851-140173514
RGD1305254 (ENSRNOG00000012442)
1:140203040-140270662
Fam108c1 (ENSRNOG00000012683)
1:140382431-140423393
Arnt2 (ENSRNOG00000013017)
1:140535823-140693148
FAAA_RAT (ENSRNOG00000013223)
1:140851979-140876087
Zfand6 (ENSRNOG00000013506)
1:140885729-140960486
Olr10 (ENSRNOG00000029100)
1:141151954-141152901
Olr11 (ENSRNOG00000032046)
1:141497719-141498669
Vom2r40 (ENSRNOG00000030229)
1:141602289-141721711
Vom2r41 (ENSRNOG00000028804)
1:141861806-141914331
Vom2r42 (ENSRNOG00000043159)
1:142010227-142055405
Vom2r43 (ENSRNOG00000013563)
1:142267794-142290322
Olr12 (ENSRNOG00000033009)
1:142339329-142340252
Olr13 (ENSRNOG00000032371)
1:142363442-142364368
Olr14 (ENSRNOG00000030565)
1:142393184-142394125
Olr16 (ENSRNOG00000031741)
1:142435591-142436541
Olr17 (ENSRNOG00000030774)
1:142443502-142444458
Olr19 (ENSRNOG00000032077)
1:142491573-142492532
D4A8P2_RAT (ENSRNOG00000024653)
1:142500803-142501792
Olr20 (ENSRNOG00000032843)
1:142539267-142540259
Olr23 (ENSRNOG00000029907)
1:142677366-142678361
Olr24 (ENSRNOG00000031858)
1:142710362-142711303
Olr25 (ENSRNOG00000028897)
1:142740112-142741104
Olr27 (ENSRNOG00000033105)
1:142782825-142783766
D3ZPM8_RAT (ENSRNOG00000032179)
1:142795102-142800862
Olr29 (ENSRNOG00000030176)
1:142819617-142820624
Olr30 (ENSRNOG00000029233)
1:142835594-142836523
Olr32 (ENSRNOG00000033463)
1:142871429-142872436
Olr34 (ENSRNOG00000030554)
1:142922930-142923868
Folh1 (ENSRNOG00000013770)
1:142936379-143010358
F1M627_RAT (ENSRNOG00000021928)
1:142990978-142991758
LOC682236 (ENSRNOG00000033507)
1:143105977-143137062
F1M7J6_RAT (ENSRNOG00000028905)
1:143224045-143225319
Nox4 (ENSRNOG00000013925)
1:143415816-143603546
Tyr (ENSRNOG00000016421)
1:143641257-143746315
Grm5 (ENSRNOG00000016429)
1:143863506-144477283
Ctsc (ENSRNOG00000016496)
1:144629802-144661183
Rab38 (ENSRNOG00000016769)
1:144783909-144864574
F1M7E7_RAT (ENSRNOG00000031869)
1:144968576-144968944
Tmem135 (ENSRNOG00000016815)
1:145664797-145894704
Fzd4 (ENSRNOG00000016848)
1:145953746-145957666
Prss23 (ENSRNOG00000017307)
1:146081557-146089928
F1M6N3_RAT (ENSRNOG00000017296)
1:146082484-146082870
F1LUQ4_RAT (ENSRNOG00000017311)
1:146313072-146422586
D4A6D5_RAT (ENSRNOG00000031186)
1:146425722-146426346

Homo sapiens
Homologues
Location
RP11-382A20.3 (ENSG00000166503) 15:83784320-83876770
BNC1 (ENSG00000169594)
15:83924655-83953466
SH3GL3 (ENSG00000140600)
15:84115980-84287495
ADAMTSL3 (ENSG00000156218)
15:84322838-84708594
FAM154B (ENSG00000188659)
15:82555151-82577271
EFTUD1 (ENSG00000140598)
15:82422571-82555104
MEX3B (ENSG00000183496)
15:82334119-82338482
No homologues
TMC3 (ENSG00000188869)
15:81623558-81666554
STARD5 (ENSG00000172345)
15:81601394-81616524
IL16 (ENSG00000172349)
15:81451916-81605104
C15orf26 (ENSG00000156206)
15:81299374-81441516
MESDC1 (ENSG00000140406)
15:81293295-81296342
MESDC2 (ENSG00000117899)
15:81239667-81282219
KIAA1199 (ENSG00000103888)
15:81071684-81244117
FAM108C1 (ENSG00000136379)
15:80972025-81047962
ARNT2 (ENSG00000172379)
15:80696692-80890278
FAH (ENSG00000103876)
15:80444832-80479288
ZFAND6 (ENSG00000086666)
15:80351910-80430735
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
OR13G1 (ENSG00000197437)
1:247835320-247836365
OR6F1 (ENSG00000169214)
1:247875045-247876105
OR14A2 (ENSG00000241128)
1:247886401-247887345
OR14A2 (ENSG00000241128)
1:247886401-247887345
No homologues
No homologues
No homologues
No homologues
No homologues
OR14A2 (ENSG00000241128)
1:247886401-247887345
No homologues
OR14A2 (ENSG00000241128)
1:247886401-247887345
No homologues
OR14A2 (ENSG00000241128)
1:247886401-247887345
No homologues
OR14A2 (ENSG00000241128)
1:247886401-247887345
No homologues
FOLH1 (ENSG00000086205)
11:49168187-49230222
No homologues
No homologues
No homologues
NOX4 (ENSG00000086991)
11:89057524-89322779
TYR (ENSG00000077498)
11:88910620-89028908
GRM5 (ENSG00000168959)
11:88237744-88799113
CTSC (ENSG00000109861)
11:88026773-88070955
RAB38 (ENSG00000123892)
11:87846431-87908635
No homologues
TMEM135 (ENSG00000166575)
11:86748886-87034756
FZD4 (ENSG00000174804)
11:86656721-86666433
PRSS23 (ENSG00000150687)
11:86502101-86663886
No homologues
ME3 (ENSG00000151376)
11:86152150-86383678
No homologues
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Table 3. List of Genes and Genomic Position in the Rat Mcs3 Locus and in the
Orthologous Human Region Obtained Using Ensembl Genome Browser (continued)

Rattus norvegicus
Genes
Location
D4ADM4_RAT (ENSRNOG00000033733)
1:146430328-146487051
LOC680217 (ENSRNOG00000022941)
1:146506681-146507085
LOC293103 (ENSRNOG00000017383)
1:146522015-146545246
Eed (ENSRNOG00000017509)
1:146563964-146591042
Picalm (ENSRNOG00000018322)
1:146754045-146834296
LOC680270 (ENSRNOG00000022808)
1:146869691-146919120
F1LN23_RAT (ENSRNOG00000030776)
1:146977959-147084664
Ccdc89 (ENSRNOG00000022766)
1:147091688-147092949
Crebzf (ENSRNOG00000018987)
1:147124224-147129115
Tmem126a (ENSRNOG00000022748)
1:147129335-147137259
Tmem126b (ENSRNOG00000022732)
1:147146187-147158120
Dlg2 (ENSRNOG00000022635)
1:148051658-149274633
F1LZX0_RAT (ENSRNOG00000033242)
1:149145746-149173468
F1M2B1_RAT (ENSRNOG00000022627)
1:149355092-149356667
Ccdc90b (ENSRNOG00000009462)
Ankrd42 (ENSRNOG00000009664)
Pcf11 (ENSRNOG00000009891)
Rab30 (ENSRNOG00000010224)
RGD1559690 (ENSRNOG00000022521)
Prcp (ENSRNOG00000010630)
F1M1I2_RAT (ENSRNOG00000023369)
Fam181b (ENSRNOG00000010763)
RGD1561957 (ENSRNOG00000032343)
D4A3T7_RAT (ENSRNOG00000025368)
Odz4 (ENSRNOG00000011151)
Nars2 (ENSRNOG00000011476)
Gab2 (ENSRNOG00000011882)
D4AAA3_RAT (ENSRNOG00000024961)
Kctd21 (ENSRNOG00000024793)
Alg8 (ENSRNOG00000012292)
Ndufc2 (ENSRNOG00000012383)

1:149410497-149424047
1:149423846-149468863
1:149475611-149501027
1:149656373-149670208
1:149685958-149710264
1:149711289-149763868
1:149785072-149786082
1:149955641-149957129
1:151354250-151354732
1:153438818-153439081
1:153808625-154172717
1:154216134-154329582
1:154348781-154544906
1:154549903-154565904
1:154587686-154588566
1:154607442-154628226
1:154635889-154642111

Thrsp (ENSRNOG00000012404)
D4AAA7_RAT (ENSRNOG00000036873)
Kctd14 (ENSRNOG00000012494)
D3ZZQ6_RAT (ENSRNOG00000012552)
RGD1561459 (ENSRNOG00000012584)
D3ZGQ8_RAT (ENSRNOG00000024194)
Clns1a (ENSRNOG00000012788)
Aqp11 (ENSRNOG00000013358)
Pak1 (ENSRNOG00000029784)
F1M812_RAT (ENSRNOG00000028470)
D4AB24_RAT (ENSRNOG00000013641)
Capn5 (ENSRNOG00000014251)
B3gnt6 (ENSRNOG00000014471)
Acer3 (ENSRNOG00000036866)
Tsku (ENSRNOG00000027784)
F1M245_RAT (ENSRNOG00000015058)
Lrrc32 (ENSRNOG00000015310)
D4AC97_RAT (ENSRNOG00000015560)
Prkrir (ENSRNOG00000015808)
Wnt11 (ENSRNOG00000015982)
RGD1561870 (ENSRNOG00000042782)
D3ZKE1_RAT (ENSRNOG00000016206)
Dgat2 (ENSRNOG00000016573)
Mogat2 (ENSRNOG00000027228)
Map6 (ENSRNOG00000027204)

1:154647341-154651663
1:154660657-154661255
1:154684785-154690800
1:154714605-154778361
1:154786525-154800839
1:154817662-154935717
1:154946673-154966945
1:154973798-154983989
1:155057622-155174708
1:155199289-155253342
1:155292620-155362698
1:155366703-155421183
1:155435459-155440490
1:155455466-155509236
1:155611070-155622378
1:155716478-155747851
1:155761334-155771294
1:155862045-155931127
1:155982782-155997548
1:156126223-156140802
1:156142284-156142592
1:156174285-156435696
1:156447588-156478740
1:156516533-156540899
1:156592504-156657997

Homo sapiens
Homologues
Location
CCDC81 (ENSG00000149201)
11:86085778-86134151
No homologues
C11orf73 (ENSG00000149196)
11:86013253-86056969
EED (ENSG00000074266)
11:85955586-85989781
PICALM (ENSG00000073921)
11:85668727-85780924
CCDC83 (ENSG00000150676)
11:85566144-85631064
SYTL2 (ENSG00000137501)
11:85405267-85522184
CCDC89 (ENSG00000179071)
11:85394893-85397320
CREBZF (ENSG00000137504)
11:85370752-85393951
TMEM126A (ENSG00000171202)
11:85359011-85367591
TMEM126B (ENSG00000171204)
11:85339629-85347580
DLG2 (ENSG00000150672)
11:83166055-85338966
No homologues
RP11-574F21.3 (ENSG00000258465) 1:160187254-160254920
DCAF8 (ENSG00000132716)
1:160185505-160254920
CCDC90B (ENSG00000137500)
11:82970139-82997450
ANKRD42 (ENSG00000137494)
11:82904754-82971736
PCF11 (ENSG00000165494)
11:82868030-82898493
RAB30 (ENSG00000137502)
11:82684175-82782965
C11orf82 (ENSG00000165490)
11:82611017-82669319
PRCP (ENSG00000137509)
11:82534544-82681626
No homologues
FAM181B (ENSG00000182103)
11:82443053-82444906
No homologues
No homologues
ODZ4 (ENSG00000149256)
11:78363876-79151992
NARS2 (ENSG00000137513)
11:78147007-78285919
GAB2 (ENSG00000033327)
11:77926343-78129394
USP35 (ENSG00000118369)
11:77899858-77925757
KCTD21 (ENSG00000188997)
11:77882295-77899868
ALG8 (ENSG00000159063)
11:77811982-77850706
NDUFC2 (ENSG00000151366)
11:77779350-77791265
NDUFC2-KCTD14 (ENSG00000259112)11:77728017-77790911
THRSP (ENSG00000151365)
11:77774907-77779397
PRDX2 (ENSG00000167815)
19:12907634-12912694
KCTD14 (ENSG00000151364)
11:77726761-77757237
INTS4 (ENSG00000149262)
11:77589766-77705724
C11orf67 (ENSG00000087884)
11:77532155-77629478
RSF1 (ENSG00000048649)
11:77371041-77532063
CLNS1A (ENSG00000074201)
11:77225981-77348850
AQP11 (ENSG00000178301)
11:77300436-77321400
PAK1 (ENSG00000149269)
11:77032752-77185680
GDPD4 (ENSG00000178795)
11:76927603-77012732
MYO7A (ENSG00000137474)
11:76839310-76926284
CAPN5 (ENSG00000149260)
11:76777979-76837201
B3GNT6 (ENSG00000198488)
11:76745385-76753096
ACER3 (ENSG00000078124)
11:76571911-76737841
TSKU (ENSG00000182704)
11:76493295-76509198
No homologues
LRRC32 (ENSG00000137507)
11:76368568-76381791
C11orf30 (ENSG00000158636)
11:76155967-76264069
PRKRIR (ENSG00000137492)
11:76061000-76092015
WNT11 (ENSG00000085741)
11:75897369-75921803
No homologues
UVRAG (ENSG00000198382)
11:75526212-75854239
DGAT2 (ENSG00000062282)
11:75470557-75512579
MOGAT2 (ENSG00000166391)
11:75428864-75444003
MAP6 (ENSG00000171533)
11:75297963-75380165
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Table 3. List of Genes and Genomic Position in the Rat Mcs3 Locus and in the
Orthologous Human Region Obtained Using Ensembl Genome Browser (continued)

Rattus norvegicus
Genes
Location
Serpinh1 (ENSRNOG00000016831)
1:156667042-156674221
B5DF39_RAT (ENSRNOG00000036859)
1:156703241-156794530
Klhl35 (ENSRNOG00000017365)
1:156801077-156806657
Rps3 (ENSRNOG00000017418)
1:156811473-156816770
Arrb1 (ENSRNOG00000030404)
1:156871562-156937540
LOC681316 (ENSRNOG00000017922)
1:156958285-156959444
Slco2b1 (ENSRNOG00000017976)
1:156992493-157028887
Q5RJS1_RAT (ENSRNOG00000018071)
1:157074498-157076449
Olr36 (ENSRNOG00000030788)
1:157085954-157086934
Olr37 (ENSRNOG00000018078)
1:157123043-157124008
Neu3 (ENSRNOG00000018106)
1:157172548-157183064
Spcs2 (ENSRNOG00000018164)
1:157199447-157217395
F1MAJ1_RAT (ENSRNOG00000026503)
1:157217625-157281411
LOC685009 (ENSRNOG00000026408)
1:157289186-157313991
LOC100360934 (ENSRNOG00000018394)
1:157391482-157399282
Pold3 (ENSRNOG00000018411)
1:157453059-157490563
Lipt2 (ENSRNOG00000016906)
1:157538704-157541031
Kcne3 (ENSRNOG00000017054)
1:157558044-157565007
Pgm2l1 (ENSRNOG00000017079)
1:157605906-157655227
P4ha3 (ENSRNOG00000017118)
1:157663338-157720713
Ppme1 (ENSRNOG00000017227)
1:157725633-157773879
D3ZXD6_RAT (ENSRNOG00000017608)
1:157774329-157892686
Ucp3 (ENSRNOG00000017716)
1:157896001-157909606
Ucp2 (ENSRNOG00000017854)
1:157922179-157928518
Dnajb13 (ENSRNOG00000017975)
1:157931501-157945870
Chchd8 (ENSRNOG00000025385)
1:157965119-157968347
Mrpl48 (ENSRNOG00000018042)
1:157979818-158022405
Rab6a (ENSRNOG00000018176)
1:158041088-158080213
Plekhb1 (ENSRNOG00000018627)
Fam168a (ENSRNOG00000018873)
Relt (ENSRNOG00000025075)
D4ADZ1_RAT (ENSRNOG00000019192)
P2ry6 (ENSRNOG00000019270)
P2ry2 (ENSRNOG00000019283)
Fchsd2 (ENSRNOG00000019319)
Q6QI52_RAT (ENSRNOG00000033196)
Atg16l2 (ENSRNOG00000019413)
Stard10 (ENSRNOG00000019491)
F1LM60_RAT (ENSRNOG00000019555)
Pde2a (ENSRNOG00000019560)
Art2 (ENSRNOG00000019687)
F1LXX4_RAT (ENSRNOG00000042674)
Clpb (ENSRNOG00000019693)
Phox2a (ENSRNOG00000019706)
Inppl1 (ENSRNOG00000019730)
Folr2 (ENSRNOG00000019890)
Folr1 (ENSRNOG00000019902)
RGD1311634 (ENSRNOG00000019936)
Lrtomt (ENSRNOG00000023434)
MGC72560 (ENSRNOG00000020016)
Lrrc51 (ENSRNOG00000020124)
F1LW91_RAT (ENSRNOG00000000417)
Il18bp (ENSRNOG00000020150)
Rnf121 (ENSRNOG00000020175)
TRPC2_RAT (ENSRNOG00000020188)
F1M3Z1_RAT (ENSRNOG00000036817)
Art5 (ENSRNOG00000020242)

1:158081930-158099517
1:158140473-158287606
1:158293361-158300581
1:158316868-158375737
1:158381128-158406783
1:158440062-158446040
1:158548830-158782422
1:158590389-158593205
1:158787779-158800330
1:158819970-158845080
1:158846702-158912163
1:158921607-159013829
1:159055461-159058780
1:159116498-159117496
1:159126512-159246279
1:159273524-159277731
1:159278130-159291910
1:159295773-159300030
1:159315192-159324141
1:159359110-159362843
1:159362010-159364059
1:159367471-159373042
1:159373973-159393171
1:159435751-159470959
1:159471809-159473288
1:159475046-159542451
1:159542820-159576982
1:159546441-159547441
1:159576991-159586949

Homo sapiens
Homologues
Location
SERPINH1 (ENSG00000149257)
11:75273101-75283828
GDPD5 (ENSG00000158555)
11:75145685-75236948
KLHL35 (ENSG00000149243)
11:75133438-75141674
No homologues
ARRB1 (ENSG00000137486)
11:74975226-75062873
No homologues
SLCO2B1 (ENSG00000137491)
11:74811608-74917594
OR2AT4 (ENSG00000171561)
11:74799758-74800799
No homologues
No homologues
NEU3 (ENSG00000162139)
11:74699179-74729938
SPCS2 (ENSG00000118363)
11:74660292-74690076
XRRA1 (ENSG00000166435)
11:74518784-74660245
RNF169 (ENSG00000166439)
11:74459913-74553458
CHRDL2 (ENSG00000054938)
11:74407474-74442430
POLD3 (ENSG00000077514)
11:74204896-74380162
LIPT2 (ENSG00000175536)
11:74202757-74204778
KCNE3 (ENSG00000175538)
11:74165886-74178774
PGM2L1 (ENSG00000165434)
11:74041363-74109518
P4HA3 (ENSG00000149380)
11:73946846-74022702
PPME1 (ENSG00000214517)
11:73882144-73965748
C2CD3 (ENSG00000168014)
11:73723763-73882255
UCP3 (ENSG00000175564)
11:73711326-73720480
UCP2 (ENSG00000175567)
11:73685712-73694352
DNAJB13 (ENSG00000187726)
11:73661364-73681411
CHCHD8 (ENSG00000181924)
11:73583712-73588033
MRPL48 (ENSG00000175581)
11:73498361-73576178
RAB6A (ENSG00000175582)
11:73386938-73472182
RAB6C (ENSG00000222014)
2:130737235-130740311
PLEKHB1 (ENSG00000021300)
11:73357223-73373864
FAM168A (ENSG00000054965)
11:73111532-73309234
RELT (ENSG00000054967)
11:73087309-73108519
ARHGEF17 (ENSG00000110237)
11:73019334-73080136
P2RY6 (ENSG00000171631)
11:72975550-73009662
P2RY2 (ENSG00000175591)
11:72929343-72947397
FCHSD2 (ENSG00000137478)
11:72547790-72853306
No homologues
ATG16L2 (ENSG00000168010)
11:72525353-72554719
STARD10 (ENSG00000214530)
11:72465774-72505213
ARAP1 (ENSG00000186635)
11:72396114-72504644
PDE2A (ENSG00000186642)
11:72287185-72385635
No homologues
No homologues
CLPB (ENSG00000162129)
11:72003469-72145692
PHOX2A (ENSG00000165462)
11:71950121-71956708
INPPL1 (ENSG00000165458)
11:71934745-71950149
FOLR2 (ENSG00000165457)
11:71927645-71932994
FOLR1 (ENSG00000110195)
11:71900602-71907345
C11orf51 (ENSG00000110200)
11:71817424-71823826
LRTOMT (ENSG00000184154)
11:71791382-71821828
LAMTOR1 (ENSG00000149357)
11:71796941-71814433
No homologues
NUMA1 (ENSG00000137497)
11:71713910-71791739
IL18BP (ENSG00000137496)
11:71709587-71716761
RNF121 (ENSG00000137522)
11:71639747-71708643
No homologues
No homologues
ART5 (ENSG00000167311)
11:3659733-3663546
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Table 3. List of Genes and Genomic Position in the Rat Mcs3 Locus and in the
Orthologous Human Region Obtained Using Ensembl Genome Browser (continued)

Rattus norvegicus
Genes
Location
Art1 (ENSRNOG00000020251)
1:159586246-159590797
Chrna10 (ENSRNOG00000020293)
1:159590904-159595101
Nup98 (ENSRNOG00000020347)
1:159598048-159696720
Pgap2 (ENSRNOG00000020371)
1:159696920-159722558
Rhog (ENSRNOG00000020393)
1:159724016-159735532
Stim1 (ENSRNOG00000020425)
1:159761567-159925836
Olr40 (ENSRNOG00000018541)
1:160090914-160091975
Olr41 (ENSRNOG00000012071)
1:160145884-160146825
Trim21 (ENSRNOG00000018517)
1:160175882-160187661
Olr43 (ENSRNOG00000018514)
1:160208359-160209309
Olr44 (ENSRNOG00000018512)
1:160220248-160221195
Olr45 (ENSRNOG00000018508)
1:160237160-160238113
Olr46 (ENSRNOG00000018506)
1:160247696-160248640
LOC293190 (ENSRNOG00000018503)
1:160254067-160254579
Olr47 (ENSRNOG00000018501)
1:160258278-160259237
Olr48 (ENSRNOG00000018497)
1:160275366-160276438
Olr49 (ENSRNOG00000015444)
1:160489681-160490646
D3ZYR2_RAT (ENSRNOG00000015432)
1:160503871-160527438
Olr51 (ENSRNOG00000015424)
1:160512753-160513703
Olr53 (ENSRNOG00000031110)
1:160547823-160548767
Olr56 (ENSRNOG00000015412)
1:160573393-160574343
Olr57 (ENSRNOG00000015407)
1:160580940-160581884
Olr59 (ENSRNOG00000018606)
1:160607895-160613802
Olr60 (ENSRNOG00000029206)
1:160626353-160627315
Olr61 (ENSRNOG00000033046)
1:160634724-160635686
Olr62 (ENSRNOG00000031787)
1:160643870-160644832
Olr63 (ENSRNOG00000018551)
1:160647966-160648919
Olr67 (ENSRNOG00000034083)
1:160746318-160747394
Olr68 (ENSRNOG00000015649)
1:160765772-160766740
Olr69 (ENSRNOG00000015657)
1:160771342-160773093
Olr70 (ENSRNOG00000015673)
1:160788683-160789624
F1LWR7_RAT (ENSRNOG00000015681)
1:160805014-160813315
Olr74 (ENSRNOG00000015689)
1:160825660-160826619
Olr75 (ENSRNOG00000030860)
1:160833798-160834757
Olr77 (ENSRNOG00000029270)
1:160853088-160854047
Olr78 (ENSRNOG00000015760)
1:160866763-160867710
Olr79 (ENSRNOG00000015764)
1:160873701-160874642
Olr80 (ENSRNOG00000015769)
1:160911661-160912676
Olr81 (ENSRNOG00000028970)
1:160922554-160923492
Olr82 (ENSRNOG00000033200)
1:160937940-160938884
Olr83 (ENSRNOG00000031586)
1:160955735-160956673
Olr84 (ENSRNOG00000030275)
1:160970408-160971391
Olr85 (ENSRNOG00000015785)
1:160977271-160978206
Olr86 (ENSRNOG00000021332)
1:161007450-161008388
Olr87 (ENSRNOG00000021290)
1:161019428-161020366
Olr91 (ENSRNOG00000015804)
1:161076388-161077344
Olr92 (ENSRNOG00000015811)
1:161084121-161085065
Olr93 (ENSRNOG00000015819)
1:161092784-161093728
Olr94 (ENSRNOG00000036811)
1:161099003-161099974
Olr95 (ENSRNOG00000036810)
1:161107309-161108253
Olr96 (ENSRNOG00000015832)
1:161117890-161118846
Olr97 (ENSRNOG00000011001)
1:161128788-161130043
Olr98 (ENSRNOG00000033060)
1:161149322-161150269
F1LUF0_RAT (ENSRNOG00000043307)
1:161165381-161185205
Olr101 (ENSRNOG00000031820)
1:161175882-161176832
Olr103 (ENSRNOG00000030169)
1:161204913-161205863
Olr104 (ENSRNOG00000015876)
1:161216105-161217064
Olr105 (ENSRNOG00000015885)
1:161229983-161230930

Homo sapiens
Homologues
Location
ART1 (ENSG00000129744)
11:3666358-3685646
CHRNA10 (ENSG00000129749)
11:3686817-3692614
NUP98 (ENSG00000110713)
11:3692313-3819022
PGAP2 (ENSG00000148985)
11:3818954-3847601
RHOG (ENSG00000177105)
11:3848208-3862213
STIM1 (ENSG00000167323)
11:3875757-4114439
No homologues
OR52B4 (ENSG00000221996)
11:4388493-4389616
TRIM21 (ENSG00000132109)
11:4406127-4414926
No homologues
No homologues
OR52K2 (ENSG00000181963)
11:4470525-4471591
OR52K1 (ENSG00000196778)
11:4510109-4511138
BCL2L1 (ENSG00000171552)
20:30252255-30311792
No homologues
OR52M1 (ENSG00000197790)
11:4566421-4567374
OR51S1 (ENSG00000176922)
11:4869427-4870514
OR51F1 (ENSG00000188069)
11:4790209-4791168
OR51F2 (ENSG00000176925)
11:4842551-4843686
No homologues
OR51C1P (ENSG00000197674)
11:4711988-4713394
AC103710.1 (ENSG00000197426)
11:4730835-4731698
OR51E2 (ENSG00000167332)
11:4701401-4719084
No homologues
No homologues
No homologues
OR51E1 (ENSG00000180785)
11:4664650-4676718
OR51A7 (ENSG00000176895)
11:4928600-4965356
OR51A7 (ENSG00000176895)
11:4928600-4965356
OR51G2 (ENSG00000176893)
11:4935900-4936922
OR51G1 (ENSG00000176879)
11:4944531-4945637
No homologues
OR52R1 (ENSG00000176937)
11:4824663-4825847
OR51F1 (ENSG00000188069)
11:4790209-4791168
OR51F1 (ENSG00000188069)
11:4790209-4791168
OR51L1 (ENSG00000176798)
11:5020213-5021160
No homologues
OR52E2 (ENSG00000176787)
11:5079880-5080857
OR52J3 (ENSG00000205495)
11:5067756-5068691
No homologues
OR52J3 (ENSG00000205495)
11:5067756-5068691
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
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Table 3. List of Genes and Genomic Position in the Rat Mcs3 Locus and in the
Orthologous Human Region Obtained Using Ensembl Genome Browser (continued)

Rattus norvegicus
Genes
Location
Olr106 (ENSRNOG00000015893)
1:161240522-161241493
Olr107 (ENSRNOG00000015901)
1:161253006-161254085
Olr108 (ENSRNOG00000015909)
1:161270136-161271077
Olr109 (ENSRNOG00000015919)
1:161273981-161274934
Olr110 (ENSRNOG00000015924)
1:161286481-161287446
Olr111 (ENSRNOG00000015926)
1:161318671-161319618
Olr112 (ENSRNOG00000015933)
1:161330800-161331762
Olr113 (ENSRNOG00000015940)
1:161340241-161341182
Olr114 (ENSRNOG00000032357)
1:161347591-161348535
Olr115 (ENSRNOG00000031878)
1:161362778-161363731
F1M0A2_RAT (ENSRNOG00000015966)
1:161377757-161378526
D3ZMJ6_RAT (ENSRNOG00000042552)
1:161418106-161419072
Olr119 (ENSRNOG00000033350)
1:161432556-161433509
Olr120 (ENSRNOG00000031550)
1:161440488-161441432
Olr121 (ENSRNOG00000030395)
1:161457068-161458021
Olr122 (ENSRNOG00000029978)
1:161468297-161469247
F1M2P3_RAT (ENSRNOG00000032984)
1:161482950-161483890
Olr124 (ENSRNOG00000016018)
1:161490750-161491697
Olr125 (ENSRNOG00000016027)
1:161506536-161507495
Olr126 (ENSRNOG00000029612)
1:161520711-161521661
Olr127 (ENSRNOG00000034039)
1:161542787-161543734
Olr128 (ENSRNOG00000016052)
1:161566055-161567017
LOC689064 (ENSRNOG00000031230)
1:161578128-161579492
Hbb (ENSRNOG00000033465)

1:161584858-161620198

Hbb-b1 (ENSRNOG00000025510)

1:161590671-161598127

Hbg1 (ENSRNOG00000030879)
Hbe2 (ENSRNOG00000030784)
Hbe1 (ENSRNOG00000029286)
Olr129 (ENSRNOG00000025163)
Olr130 (ENSRNOG00000031983)
Olr131 (ENSRNOG00000030179)
Olr132 (ENSRNOG00000029051)
Olr135 (ENSRNOG00000043392)
Olr136 (ENSRNOG00000024877)
LOC499219 (ENSRNOG00000024789)
Olr137 (ENSRNOG00000034041)
Olr139 (ENSRNOG00000031147)
Olr141 (ENSRNOG00000016946)
Olr142 (ENSRNOG00000016954)
Olr143 (ENSRNOG00000016964)
Olr144 (ENSRNOG00000016979)
F1LZ60_RAT (ENSRNOG00000023979)
Olr148 (ENSRNOG00000016993)
RGD1562433 (ENSRNOG00000036807)
Ubqln3 (ENSRNOG00000023833)
Ubqlnl (ENSRNOG00000017016)
RGD1310717 (ENSRNOG00000017039)
Olr149 (ENSRNOG00000017138)
Olr150 (ENSRNOG00000017143)
Trim6 (ENSRNOG00000017147)
D3ZA88_RAT (ENSRNOG00000042686)

1:161640240-161641771
1:161647651-161649279
1:161651306-161652708
1:161677418-161678353
1:161687005-161687928
1:161697243-161698166
1:161717426-161718373
1:161758920-161759858
1:161771509-161772462
1:161788384-161794974
1:161796236-161797201
1:161825890-161826855
1:161856623-161857573
1:161872355-161873299
1:161883447-161884385
1:161890517-161891461
1:161912324-161913262
1:161948171-161949142
1:161962308-161963840
1:161974585-161977032
1:161985144-161986982
1:161990223-161998056
1:162014526-162015476
1:162032269-162033207
1:162066157-162072075
1:162086771-162093563

Trim5 (ENSRNOG00000017191)
F1LV70_RAT (ENSRNOG00000036804)
Trim30 (ENSRNOG00000042947)

1:162096454-162113409
1:162142545-162143057
1:162173307-162174453

Homo sapiens
Homologues
Location
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
NRBF2 (ENSG00000148572)
10:64893050-64914783
No homologues
OR51B6 (ENSG00000176239)
11:5344961-5373676
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
OR52A5 (ENSG00000171944)
11:5152922-5153872
OR52A5 (ENSG00000171944)
11:5152922-5153872
No homologues
HBD (ENSG00000223609)
11:5253908-5256600
HBB (ENSG00000244734)
11:5246694-5250625
HBD (ENSG00000223609)
11:5253908-5256600
HBB (ENSG00000244734)
11:5246694-5250625
HBD (ENSG00000223609)
11:5253908-5256600
HBB (ENSG00000244734)
11:5246694-5250625
No homologues
No homologues
HBE1 (ENSG00000213931)
11:5289582-5526847
No homologues
No homologues
No homologues
OR51B6 (ENSG00000176239)
11:5344961-5373676
No homologues
OR51J1 (ENSG00000184321)
11:5423827-5424777
No homologues
OR51Q1 (ENSG00000167360)
11:5443341-5444436
OR51Q1 (ENSG00000167360)
11:5443341-5444436
No homologues
OR51I1 (ENSG00000167359)
11:5451898-5489943
OR51I2 (ENSG00000187918)
11:5474638-5475707
No homologues
No homologues
OR52D1 (ENSG00000181609)
11:5509915-5510979
No homologues
UBQLN3 (ENSG00000175520)
11:5528530-5531215
UBQLNL (ENSG00000175518)
11:5535623-5537935
No homologues
OR52H1 (ENSG00000181616)
11:5565719-5566779
No homologues
TRIM6 (ENSG00000121236)
11:5617339-5634188
TRIM6-TRIM34 (ENSG00000258588) 11:5617955-5665628
TRIM34 (ENSG00000258659)
11:5617946-5665628
TRIM5 (ENSG00000132256)
11:5684425-5959849
No homologues
No homologues
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Table 3. List of Genes and Genomic Position in the Rat Mcs3 Locus and in the
Orthologous Human Region Obtained Using Ensembl Genome Browser (continued)
Rattus norvegicus
Genes
Location
D4A0Y0_RAT (ENSRNOG00000031202)
1:162183971-162184423
D3ZA96_RAT (ENSRNOG00000024179)
1:162195024-162196352
Olr152 (ENSRNOG00000017211)
1:162202138-162203079
Olr153 (ENSRNOG00000017214)
1:162211898-162212872
Olr154 (ENSRNOG00000017218)
1:162225307-162226260
Olr156 (ENSRNOG00000017239)
1:162247587-162248513
Olr157 (ENSRNOG00000017252)
1:162265829-162267222
Olr158 (ENSRNOG00000017261)
1:162286565-162287524
Olr159 (ENSRNOG00000031557)
1:162294975-162295946
Olr160 (ENSRNOG00000031490)
1:162309721-162310695
Olr161 (ENSRNOG00000029963)
1:162319179-162320138
Olr162 (ENSRNOG00000034173)
1:162332962-162333921
D3ZLJ1_RAT (ENSRNOG00000032841)
1:162340898-162342106
Olr163 (ENSRNOG00000031012)
1:162349312-162350277
Usp17l5 (ENSRNOG00000043303)
1:162371236-162372750

Olr164 (ENSRNOG00000033899)
Olr165 (ENSRNOG00000032268)
Olr168 (ENSRNOG00000029647)
Olr170 (ENSRNOG00000029375)
LOC689730 (ENSRNOG00000017288)

1:162392486-162393451
1:162420209-162421177
1:162486804-162487763
1:162510151-162511116
1:162540440-162549650

Homo sapiens
Homologues
Location
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
OR56B1 (ENSG00000181023)
11:5757681-5758768
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
USP17L2 (ENSG00000223443)
8:11994677-11996586
RP11-1396O13.9 (ENSG00000231637) 4:9355364-9356956
RP11-1396O13.8 (ENSG00000231051) 4:9350619-9352211
RP11-1396O13.7 (ENSG00000235780) 4:9345874-9347466
RP11-1396O13.5 (ENSG00000229579) 4:9336384-9337976
USP17 (ENSG00000232264)
4:9326891-9328483
RP11-1396O13.4 (ENSG00000230430) 4:9331637-9333229
RP11-1396O13.11 (ENSG00000228856)4:9364855-9366447
USP17L5 (ENSG00000227140)
4:9341129-9342721
RP11-1286E23.15 (ENSG00000250745)4:9259850-9261442
RP11-1286E23.6 (ENSG00000233136) 4:9217131-9218723
RP11-1286E23.17 (ENSG00000248933)4:9269345-9270937
RP11-1286E23.14 (ENSG00000248920)4:9255104-9256696
RP11-1286E23.13 (ENSG00000250844)4:9250356-9251948
RP11-1286E23.16 (ENSG00000249811)4:9264598-9266190
RP11-1286E23.7 (ENSG00000227551) 4:9221878-9223470
RP11-1286E23.10 (ENSG00000223569)4:9236111-9237700
RP11-1286E23.8 (ENSG00000232399) 4:9212383-9228214
RP11-1286E23.12 (ENSG00000249104)4:9245605-9247197
RP11-1286E23.5 (ENSG00000231396) 4:9212383-9213975
RP11-1286E23.18 (ENSG00000250913)4:9274090-9274640
OR52N1 (ENSG00000181001)
11:5809084-5810046
No homologues
No homologues
OR52N1 (ENSG00000181001)
11:5809084-5810046
USP17L2 (ENSG00000223443)
8:11994677-11996586
RP11-1396O13.9 (ENSG00000231637) 4:9355364-9356956
RP11-1396O13.8 (ENSG00000231051) 4:9350619-9352211
RP11-1396O13.7 (ENSG00000235780) 4:9345874-9347466
RP11-1396O13.5 (ENSG00000229579) 4:9336384-9337976
USP17 (ENSG00000232264)
4:9326891-9328483
RP11-1396O13.4 (ENSG00000230430) 4:9331637-9333229
RP11-1396O13.11 (ENSG00000228856)4:9364855-9366447
USP17L5 (ENSG00000227140)
4:9341129-9342721
RP11-1286E23.15 (ENSG00000250745)4:9259850-9261442
RP11-1286E23.6 (ENSG00000233136) 4:9217131-9218723
RP11-1286E23.17 (ENSG00000248933)4:9269345-9270937
RP11-1286E23.14 (ENSG00000248920)4:9255104-9256696
RP11-1286E23.13 (ENSG00000250844)4:9250356-9251948
RP11-1286E23.16 (ENSG00000249811)4:9264598-9266190
RP11-1286E23.7 (ENSG00000227551) 4:9221878-9223470
RP11-1286E23.10 (ENSG00000223569)4:9236111-9237700
RP11-1286E23.8 (ENSG00000232399) 4:9212383-9228214
RP11-1286E23.12 (ENSG00000249104)4:9245605-9247197
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Table 3. List of Genes and Genomic Position in the Rat Mcs3 Locus and in the
Orthologous Human Region Obtained Using Ensembl Genome Browser (continued)
Rattus norvegicus
Location

Genes

Olr171 (ENSRNOG00000031652)
Olr172 (ENSRNOG00000030695)
Olr174 (ENSRNOG00000029040)
Olr175 (ENSRNOG00000017308)
Olr176 (ENSRNOG00000032615)
Olr178 (ENSRNOG00000017331)
Olr179 (ENSRNOG00000033989)
Olr180 (ENSRNOG00000033813)

1:162563516-162564466
1:162571258-162572214
1:162590020-162590976
1:162618317-162619282
1:162626124-162627080
1:162681198-162682136
1:162728293-162729231
1:162739521-162740471

Olr181 (ENSRNOG00000033534)
Olr183 (ENSRNOG00000027423)
Olr184 (ENSRNOG00000017341)

1:162772333-162773271
1:162782725-162783666
1:162793777-162794730

Olr185 (ENSRNOG00000017344)
Olr186 (ENSRNOG00000033218)
Olr188 (ENSRNOG00000017351)
Olr189 (ENSRNOG00000031357)
Olr190 (ENSRNOG00000017357)
LOC100362148 (ENSRNOG00000017362)
Olr192 (ENSRNOG00000017366)
Olr193 (ENSRNOG00000030947)
Olr194 (ENSRNOG00000029946)
Olr196 (ENSRNOG00000033931)
Olr197 (ENSRNOG00000017379)
Olr198 (ENSRNOG00000032010)
Olr199 (ENSRNOG00000029755)
Olr200 (ENSRNOG00000029155)
Olr201 (ENSRNOG00000017387)
Olr202 (ENSRNOG00000025819)
RGD1561034 (ENSRNOG00000030818)
Fam160a2 (ENSRNOG00000017408)
Cnga4 (ENSRNOG00000017609)
Cckbr (ENSRNOG00000017679)
Prkcdbp (ENSRNOG00000017914)
Smpd1 (ENSRNOG00000017977)
Apbb1 (ENSRNOG00000018020)
Hpx (ENSRNOG00000018257)
Trim3 (ENSRNOG00000018356)
Arfip2 (ENSRNOG00000018440)
TIM9B_RAT (ENSRNOG00000018654)
F1M5X6_RAT (ENSRNOG00000043327)
D4A4C1_RAT (ENSRNOG00000033327)
Dnhd1 (ENSRNOG00000043240)
Rrp8 (ENSRNOG00000018766)
Ilk (ENSRNOG00000018993)
Taf10 (ENSRNOG00000019178)
Tpp1 (ENSRNOG00000019212)
Dchs1 (ENSRNOG00000031643)
RM17_RAT (ENSRNOG00000019497)
D4A3E9_RAT (ENSRNOG00000042713)
RGD1308274 (ENSRNOG00000029048)
D3ZNN6_RAT (ENSRNOG00000042725)
D3ZJQ9_RAT (ENSRNOG00000042292)
D3Z9P7_RAT (ENSRNOG00000042759)
F1LZ18_RAT (ENSRNOG00000019521)
F1LV81_RAT (ENSRNOG00000036793)
Olr203 (ENSRNOG00000032322)
Olr204 (ENSRNOG00000034133)
Olr205 (ENSRNOG00000029697)

1:162803635-162804588
1:162810227-162811168
1:162835732-162836670
1:162843036-162843977
1:162857313-162858260
1:162862402-162864364
1:162881824-162882774
1:162895667-162896718
1:162927245-162928195
1:162966355-162967305
1:162986552-162987505
1:163004734-163005699
1:163021101-163022051
1:163042743-163043708
1:163069885-163070844
1:163080521-163081489
1:163107431-163110605
1:163110928-163133590
1:163137544-163141556
1:163156914-163166969
1:163212922-163214511
1:163278970-163282812
1:163282918-163299333
1:163319509-163327017
1:163331603-163362846
1:163364861-163369542
1:163369752-163372576
1:163380016-163420661
1:163433572-163436909
1:163462348-163467223
1:163477030-163481051
1:163481299-163487550
1:163487518-163488786
1:163490393-163496526
1:163497340-163517091
1:163554719-163556345
1:163589107-163590165
1:163590802-163593777
1:163594662-163595836
1:163596557-163598317
1:163695070-163696128
1:163696150-163696605
1:163767761-163768429
1:163776673-163777620
1:163833782-163834729
1:163874449-163875399

Homo sapiens
Homologues
Location
RP11-1286E23.5 (ENSG00000231396) 4:9212383-9213975
RP11-1286E23.18 (ENSG00000250913)4:9274090-9274640
No homologues
OR52N2 (ENSG00000180988)
11:5841544-5842578
OR52N2 (ENSG00000180988)
11:5841544-5842578
OR52N2 (ENSG00000180988)
11:5841544-5842578
OR52N2 (ENSG00000180988)
11:5841544-5842578
No homologues
No homologues
OR52E8 (ENSG00000183269)
11:5877904-5878964
OR52E6 (ENSG00000205409)
11:5862158-5863182
No homologues
No homologues
OR52E8 (ENSG00000183269)
11:5877904-5878964
OR52E6 (ENSG00000205409)
11:5862158-5863182
No homologues
No homologues
OR52E4 (ENSG00000180974)
11:5905501-5906527
No homologues
OR56A3 (ENSG00000184478)
11:5968570-5969591
No homologues
No homologues
No homologues
OR52L1 (ENSG00000183313)
11:6007122-6008215
OR52L1 (ENSG00000183313)
11:6007122-6008215
No homologues
AC111177.1 (ENSG00000180913)
11:6149840-6150706
AC111177.1 (ENSG00000180913)
11:6149840-6150706
AC111177.1 (ENSG00000180913)
11:6149840-6150706
AC022762.1 (ENSG00000180909)
11:6173006-6173818
OR52B2 (ENSG00000255307)
11:6190560-6191638
C11orf42 (ENSG00000180878)
11:6226796-6232362
FAM160A2 (ENSG00000051009)
11:6232565-6255941
CNGA4 (ENSG00000132259)
11:6255995-6265659
CCKBR (ENSG00000110148)
11:6280966-6293357
PRKCDBP (ENSG00000170955)
11:6340176-6341877
SMPD1 (ENSG00000166311)
11:6411655-6416228
APBB1 (ENSG00000166313)
11:6416354-6440644
HPX (ENSG00000110169)
11:6452279-6463847
TRIM3 (ENSG00000110171)
11:6469843-6495689
ARFIP2 (ENSG00000132254)
11:6496910-6502666
FXC1 (ENSG00000132286)
11:6502677-6530208
No homologues
DNHD1 (ENSG00000179532)
11:6518490-6593257
DNHD1 (ENSG00000179532)
11:6518490-6593257
RRP8 (ENSG00000132275)
11:6616305-6624850
ILK (ENSG00000166333)
11:6624961-6632102
TAF10 (ENSG00000166337)
11:6627526-6633898
TPP1 (ENSG00000166340)
11:6634000-6640692
DCHS1 (ENSG00000166341)
11:6642554-6677085
MRPL17 (ENSG00000158042)
11:6702013-6704632
No homologues
No homologues
No homologues
No homologues
No homologues
No homologues
ATMIN (ENSG00000166454)
16:81069452-81080963
No homologues
No homologues
No homologues

Position is Rattus norvegicus genome build version 3.4
Position

is

Archive

EnsEMBL

Homo

sapiens
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version

67.37

(GRCh37)

Ensemble genome browser was used to generate table 3. Table 3 lists known
genes at the rat Mcs3 locus and human orthologous loci. Public databases and published
literature were searched to identify genes at the Mcs3 human orthologous loci associated
with breast cancer. The cancer portal of Rat Genome Database was used to data mine
genes associated with breast cancer. We found three genes within the rat Mcs3 locus
and/or the human orthologous loci associated with breast carcinomas. Table 4 lists these
genes and known functions. Among these genes, Pak1, Ilk and Il18bp are common to
both humans and rats.
Discussion
The focus of this study was aligned toward providing information regarding the
genetic aspect of human breast cancer by using rat mammary carcinoma as a model. By
physically confirming and mapping rat Mcs3, a previously predicted mammary
carcinoma susceptibility locus, we sought to develop genetic strains to better understand
the genetic contribution associated with human breast cancer susceptibility, and
eventually discover the underlying mechanism associated with breast carcinogenesis. In
this study, Mcs3 was physically confirmed and mapped to a 25.8 Mb region on rat
chromosome 1 using congenic lines. The Cop Mcs3 allele was found to reduce the
mammary carcinoma susceptibility phenotype associated with the WF strain by 51%
when homozygous. In the previous study, that predicted the Mcs3 QTL, one Cop allele at
the Mcs3 QTL was predicted to reduce
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Table 4. List of Genes Associated with Breast Cancer and Genomic Position in the
Rat Mcs3 Locus and in the Orthologous Human Region

Position is Rattus norvegicus genome build version 3.4.
Position is Homo sapiens genome build version hg19.
This table displays the position of genes within the human and rat genomes. It also shows
the Gene symbol and gene name.
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mammary carcinoma susceptibility by 42% in female rats that were heterozygous at the
Mcs3 locus [173]. We did not test mammary carcinoma susceptibility in Mcs3
heterozygous congenic rats. The previous study was performed on F2 and rats from two
successive backcross generations. The difference in the susceptibility between the two
studies might be explained by either a possible degree of dominance of the Cop allele at
the Mcs3 locus, or by background Cop alleles potentially present in the females included
in the linkage analysis. In this study, Mcs3 was mapped to a 25.8 Mb region on rat
chromosome 1 between markers ENSRNOSNP2784088 to ENSRNOSNP2784322 (~25.8
Mb, 138,096,182 – 163,886,079). This region is distal to the predicted Mcs3 peak QTL
markers D1Mit11 and D1Wox6. This is not the first time that a Mcs locus has been
physically confirmed outside the predicted QTL interval. Both Mcs1b and Mcs1c are
beyond the predicted Mcs1 QTL interval [181, 197].
Different segments of the rat Mcs3 locus aligned to 4 human loci that were on
chromosomes 11 and 15, which are shown in table 2. Altogether, the rat and human
regions contained 3 annotated genes that have been shown to associate with breast
cancer, namely serine/threonine-protein kinase PAK 1 (PAK1), integrin-linked protein
kinase (ILK) and, interleukin-18-binding protein (IL18BP). Serine/threonine-protein
kinase PAK 1 (PAK1) downstream pathways play an important role in development and
maintenance of metastatic phenotypes in breast cancer cells [198]. PAK1 was also shown
to be a predictor of recurrence and tamoxifen resistance in post-menopausal breast cancer
[199]. Integrin-linked protein kinase (ILK) may be an important marker since increased
expression of ILK is associated with aggressive progression and poor prognosis of breast
cancer [200]. ILK was shown to regulate γ-secretase-mediated Notch1 activation in IL-6
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induced breast cancer stem cells [201]. Interleukin-18-binding protein (IL18BP) regulates
the activity of interleukin 18. IL-18 expression is significantly higher in malignant breast
tumor tissue as compared to breast tissue of patients with benign breast disease [202].
Another study suggests IL-18 enhances breast cancer cell migration [203].
We conclude that the predicted Mcs3 locus has been physically confirmed and
mapped to a 25.8 Mb region on the rat chromosome 1. Our analysis suggests that there
are at least three potential candidate genes located at the rat and orthologous human Mcs3
genomic region. The rat Mcs3 congenic lines developed will be useful tools to identify
Mcs3 candidate genes and study mechanisms underlying breast cancer genetic
susceptibility.
Materials and Methods
Congenic Breeding and Genotyping
Congenic lines were generated using methods previously described [175]. Briefly,
rats with selected Cop chromosome 1 segments from the predicted Mcs3 QTL were
introgressed onto a WF/NHsd genetic background. Congenic rat lines were maintained in
an Association for the Assessment and Accreditation of Laboratory Animal Care
(AAALAC) approved facility on a 12-hour light/dark cycle and provided LabDiet 5001
Rodent Diet (PMI Nutrition International) and water ad libitum. All animal protocols
were approved by the University of Louisville Animal Care and Use Committee
(Louisville, KY). Information for genetic markers defining ends of COP alleles carried by
each congenic line A, D, E and G were available at the UCSC Genome Browser
(www.genome.ucsc.edu), Rat Genome Database (http://rgd.mcw.edu/), or Table 5.
Animals were genotyped as described in [175]. Briefly, tail clips were used for DNA
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extraction and genotyping. Five to eight days after birth, the rats were toe tattooed and
tail clipped. The DNA was extracted to test the genotype at a given locus. Polymorphic
micro-satellite markers that vary between the two strains were selected and were used to
PCR amplify the variable region of genomic DNA. The amplified DNA was run on a 3%
high resolution agarose gel. After the run was complete, the gel was stained in SYBR
Gold and scanned on a Typhoon scanner. Visible bands were analyzed using
homozygous Cop and WF, and F1 DNA (heterozygous) as controls. For regions with low
density of polymorphic STS markers, informative SNP that were polymorphic between
Cop and WF rats were identified using SNPlotyper tool on Rat Genome Database
(http://rgd.mcw.edu/). Phenotyped rat DNA were sequenced to identify the genotype.
Information for SNP genetic markers defining ends of COP alleles carried by each
congenic line A and

E used for sequencing are available
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Table 5.

Table 5. Primer Sequences for Microsatellites in 25.8 Mb Region of Mcs3 Locus
T a b le 5 . P rim e r S e q u e n c e s f o r M ic ro s a t e llit e s a n d S N V in 2 5 .8 M b re g io n o f M c s 3 lo c u s
S a m u e ls o n La b
ID

T yp e

F o rwa rd P rim e r S e q u e n c e

R e v e rs e P rim e r S e q u e n c e

P o s it io n *

D1R a t27

S TS

GGGC AAGC AAAGTAC ATGGT

TC TC TC C AGC TGC AGGATTT

90282041-90282193

WF =C OP †

D1M it30

S TS

TGTC TTGGC C TC TGATTTC A

TGC TGTGTGGAC GGAGATAA

94473941-94474122

WF =C OP †

D1R a t214

S TS

GATTTTC AATC TTTTAGC AAGC A

TTTC AGTGAC AAC C AGGC TG

100034565-100034664

WF =C OP †

D1M it11

S TS

ATAAGC C AGC C C C C ATTC

C C TAC TGAAAGTGAAATGTC TGG

102532147-102532417

WF =C OP †

D1R a t32

S TS

TGAGC C ATTGAGTTGTGAGC

TGTTTTC C AAATGAAGC GTG

112148734-112149024

WF =C OP †

D1R a t381

S TS

TC AAAAGGC TAAGGC AGGAA

AGAC AAAAATGGAGGC C TC A

115368982-115369185

WF =C OP †

D1R a t320

S TS

C TC C AC ATGC AC AGGC ATAT

C TC C TAAAGGTC C C ATTGC A

119536685-119536913

WF =C OP †

D1R a t321

S TS

TGC AC C AAATTTTC TATTC C A

AC ATTTGC C TTTTTGGAC AT

127965057-127965205

WF =C OP †

D1R a t36

S TS

TTC C TGGGGTAC TC C C AC

TTC C TC TC C TTC AAC TC C TC C

128874535-128874670

WF =C OP †

D1Wo x6

S TS

C C C C ATC TATC TATC C AAC GG

C TC TGGGATGC TTTGTGAAGG

131956600-131956825

WF =C OP †

D1R a t382

S TS

GGC C GAATGC TTTC AATAGA

GGC ATAC ATGC TC AAAC TGC

132558148-132558270

WF =C OP †

D1R a t350

S TS

C C AGATGAAGGC TGATGGAC

AC AC GGTATTC AATC AGC C C

135620323-135620477

WF =C OP †

D1R a t173

S TS

GATC C C TTGAC AAGC ATGGT

GATGGAGGC AGTTTTTC C AA

145283364-145283529

WF =C OP †

D1M gh8

S TS

C C TC TGGATTC TGC C AGAAG

TTTC AAATGTAC AGGC TGAAAC A

156124625-156124741

WF =C OP †

D1R a t277

S TS

TC TGGTC TTTAC ATGTATGTGC A

TTC AC ATC AGTTTTGGC C AC

164875097-164875292

WF =C OP †

D1R a t243

S TS

TC AAC TC C C AGGGATTGTTC

C C C TGC TC TAAC C AGC AGTC

172072626-172072864

WF =C OP †

D1R a t65

S TS

TGAAGGAGAGC C AGGAATTG

C AGTC TGGGGGTAAGC AAGA

184879920-184880048

WF =C OP †

D1R a t290

S TS

GGC TGAGTTTTTC TC TGAC AC TG

GGTC TC AC TTC AGGGAGC AG

195105753-195105954

WF =C OP †

S NP
ENS R NOS NP 2783780

Va ria n t
P o s it io n *

Va ria n t

C OP

WF

GC C C GTC TC C AC TTC T

95200769

C /T

CC

TT

TTGTC C C TGAGC C TC G
S NP

GGAGTC TGGGC AC TGT

AC AC C C AGC TAGC AGG

99077826

T/A

TT

AA

S NP

GTGAGC AGC TGTTGGG

GGGAAC TC AC AC C GGA

137304344

T/C

TT

CC

S NP

AGTATC TGC C C GGTGG

GGC AAAC C GTC C TGAAA

138096182

G/A

AA

GG

S NP

TGC TTC GC C TTAAC C TG

TGC ATGTC AGAAGGGAGA

143556969

G/A

GG

AA

S NP

TGAC C TC C GTGC TAC C

AC C TGGTGTC GC TTC A

158009944

T/A

AA

TT

S NP

AAC GGGC C AATGGAATG

C C AC C AGC C C C TAAGA

163886079

G/T

GG

TT

S NP

C TGTC AC C C C AGC AC T

TGATTTGTC C C GGGGA

164656091

T/C

TT

CC

ENS R NOS NP 2783800

ENS R NOS NP 2784076

ENS R NOS NP 2784088

ENS R NOS NP 2784133

ENS R NOS NP 2784267

ENS R NOS NP 2784322

ENS R NOS NP 2784324
*

P o s it io n is R a t t u s n o rv e g ic u s

†

M ic ro s a t e llit e D N A g e n o t yp e s we re d e t e rm in e d u s in g 3 % h ig h re s o lu t io n a g a ro s e

g e n o m e b u ild v e rs io n 3 .4
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Phenotyping
Female congenic and WF/HSd (Harlan) rats were intubated with a single dose of
DMBA (65 mg DMBA/kg body mass) in sesame oil at 50-55 days of age. Mammary
carcinomas ≥ 3 × 3mm were counted at 15 weeks post-treatment.
Statistical Analysis
Mammary carcinoma multiplicity data were analyzed and congenic rat
phenotypes were compared to that of susceptible WF/NHsd controls. Mammary
carcinoma multiplicity phenotypes for more than two groups were compared using
Kruskal-Wallis nonparametric test. If this test was statistically significant (p value 
0.05), then each group was compared to the WF/NHsd control group by performing
multiple Mann-Whitney nonparametric tests. A p value of  0.05 was considered to be
significant.
Comparative Genomics
The human orthologous region and transcripts mapping to the rat Mcs3 locus
were identified using the Rat Genome Database, UCSC Genome Browser and the
Ensembl Genome Browser. The Rattus norvegicus reference genome sequence version
3.4/rn4 and Homo sapiens version GRCh37/hg19 were used. The percent of sequence
identity between the rat and the human region of interest was identified using the
‘Convert’ function at the UCSC genome browser.
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CHAPTER III
ASSESSING CONGENIC LINE 1B-11 FOR MCS1B ASSOCIATED PHENOTYPE
Introduction
This chapter focuses on rat mammary carcinoma susceptibility locus Mcs1b,
which was identified from the fine mapping of Mcs1 [181]. Mcs1 is a quantitative trait
locus (QTL) identified by linkage analysis of DMBA sensitive Wistar-Furth (WF) strain
and DMBA resistant Copenhagen (Cop) strain [181]. To genetically map the Mcs1 locus,
WF and Cop rats were bred to generate (WF x Cop) F1 rats. F1 rats were bred with WF
rats to generate backcross (BC1) rats. BC1 rats were analyzed for linkage between
polymorphic microsatellite markers and susceptibility to DMBA induced carcinogenesis,
which was measured by tumor number. The Mcs1 locus was identified on the proximal
end of rat chromosome 2. The Cop allele at the Mcs1 locus was predicted to reduce
DMBA induced rat mammary carcinoma susceptibility [172]. In an extension of this
study, BC1 rats were further backcrossed to generate BC2 rats and F1 rats were crossed
with each other to generate F2 rats. Linkage analysis, performed in these rats, physically
confirmed the locus and also confirmed that the Cop allele at the Mcs1 locus reduces
DMBA induced mammary carcinoma susceptibility [173].
The Mcs1b locus was identified by phenotyping Mcs1 congenic rats with varying
lengths of Cop allele across the Mcs1 locus on a WF genetic background. These rats were
given a single dose of DMBA at fifty to fifty five days of age and tumor number was
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counted at fifteen weeks post DMBA administration. This led to the identification of the
Mcs1a, Mcs1b, and Mcs1c loci. The Cop allele at the Mcs1b locus was identified to
reduce DMBA induced mammary carcinoma susceptibility [173]. A recent study by
denDekker et al. from our lab used Mcs1b congenic rats to define this locus to a 1.8 Mb
region of rat chromosome 2 [137]. The authors performed mammary gland transplant
assays in which mammary glands from the susceptible or resistant rats were transplanted
onto the back fat pads of rats with either a susceptible or resistant genotype. These rats
were then given a single dose of DMBA and tumor outcome was assessed post DMBA
administration. The results of this experiment showed that irrespective of the recipient
genotype, the grafts were tumor positive if the donor rat was of the susceptible genotype
[137]. Thus, Mcs1b acts in a mammary gland autonomous manner. The authors then
sequenced the open reading frames of genes present in the Mcs1b locus in the WF and
Mcs1b congenic rats. No differences were identified in the protein coding region
suggesting that Mcs1b locus could potentially function by controlling non protein coding
regions and differentially regulating gene expression between the two genotypes. Mcs1b
gene transcript levels were measured in WF and Mcs1b congenic rats. The authors found
that Map3k1, Gpbp1, Mier3 were differentially expressed between the two genotypes
without DMBA exposure, but only Mier3 was differentially expressed between the two
genotypes with DMBA. Map3k1, Gpbp1, Mier3 transcript levels were found to be lower
for the candidate genes in the Mcs1b resistant rats compared to the susceptible WF rats.
[137]. Tumor expression levels of Map3k1, Gpbp1, Il6st and Mier3 was tested. The
authors found that Mier3 was more highly expressed in tumors as compared to disease
free mammary tissue [137]. Lastly, it was also noted that Mcs1b female rats had a higher
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body weight compared to susceptible WF female rats when weighed at 12 weeks of age
[137]. In summary, Mcs1b associated phenotypes include reduced tumor number, lower
expression levels of Map3k1, Gpbp1, and Mier3 in mammary tissue compared to
susceptible WF without DMBA exposure, lower expression levels of Mier3 in mammary
tissue compared to susceptible WF with DMBA exposure and higher Mier3 expression in
mammary tumors compared to adjacent disease free mammary tissue.
It is worth noting that Mcs1b heterozygous congenic rats tested by Haag et al.
developed an average of 7.6 tumors/rat [181]; whereas, Mcs1b heterozygous congenic
rats tested by denDekker et al. developed around 5.5 tumors/rat [137]. This discrepancy
in number of tumors developed by rats that are heterozygous Cop at the Mcs1b locus,
observed in two different studies, could be due to the difference in the lengths of the
congenic segment contained in the congenic lines tested; and thus, may be indicative of a
complex genetic interaction within the Mcs1b locus. To test this hypothesis and delimit
Mcs1b to the narrowest possible interval, it is essential to continue fine mapping the
Mcs1b locus by phenotyping Mcs1b congenic lines with shorter Cop alleles. One such
recombinant generated is congenic line 1b-11 which is shown in figure 8. It was
generated by backcrossing congenic line T to the parental WF strain. Congenic line 1b-11
has a Cop allele which spans the distal end of the Mcs1b locus, which was present in the
Mcs1b rats tested by Haag et al., but was only partially present in the Mcs1b rats tested
by denDekker et al. Thus, line 1b-11 is a good candidate to test the hypothesis that the
Mcs1b locus might interact with a distal locus. To test this possibility, congenic line 1b11 will be investigated for Mcs1b associated phenotypes. Tumor multiplicity post DMBA
administration will be compared between congenic 1b-11 and WF rats. Mier3 expression
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Figure 8. WF.Cop Congenic Map that defines the Mcs1b Line 1b-11. Figure
represents varying segments on rat chromosome 2 where Mcs1b was predicted to be
located and congenic lines that were used to fine-map this locus. On the X axis, blue lines
represent informative microsatellite markers, red lines represent informative SNPs, and
green lines represent informative indels. Brown bars represent Cop alleles in congenic
lines with a resistant phenotype, white bars represent congenic lines with a unknown
phenotype, and grey bars represent a potential area of recombination where the genotype
isn’t determined. The horizontal blue bar represents the orthologous region to human
5q11.2 breast cancer risk (BRCR) associated haplotype block.
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levels in mammary tumors will be compared to adjacent disease free mammary tissue.
Mier3, Map3k1, Gpbp1 and Il6st expression levels in mammary gland will be compared
between 1b-11 and WF females at 12 weeks of age with DMBA and without DMBA
exposure. Body weights of 1b-11 rats will also be compared to that of WF rats at 12
weeks of age. The goal of this aim was to narrow the Mcs1b QTL interval and potentially
identify genetic interactions with another locus.
Results
Analysis of Congenic Line 1b-11 Set Ups
Generating Rats That Were Heterozygous Cop at the 1b-11 Locus
Initially, there was one fertile male rat that was homozygous at the 1b-11 locus.
This male was backcrossed with susceptible WF female rats. Table 6 shows that the
litters (N17 generation) obtained were heterozygous at the 1b-11 locus. The backcross
was successful with eight out of the eleven set ups produced litters (72% of set ups). The
litters were comprised of a total of 12 males and 18 females, all of which were
heterozygous at the 1b-11 locus. These heterozygous rats were inbred in an attempt to fix
this line and obtain female rats that were homozygous Cop at the 1b-11 locus.
Generating Rat That Were Homozygous Cop at the 1b-11 Locus
Rats that were heterozygous at the 1b-11 locus (N17 generation) were set up to
generate rats that were homozygous Cop at the 1b-11 locus (Table 6). Out of 41 different
set ups only nine (22% of set ups) produced litters (N17F1 generation). There were a total
of 22 males and 28 females. N17F1 rats that were homozygous Cop at the 1b-11 locus
were set up with rats that were heterozygous Cop at the 1b-11 locus to produce the next
generation (N17F2). Fourteen out of thirty five set ups (40% of set ups) generated litter.
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Table 6. Analysis of Congenic Lines 1b-11 and Mcs3 Line D Set Ups
generation

Mcs locus

N17
N17F1
N17F2
N17F3
N10F4
N10F5
N10F6
N10F7

Mcs1b
Mcs1b
Mcs1b
Mcs1b
Mcs3
Mcs3
Mcs3
Mcs3

congenic
line
1b-11
1b-11
1b-11
1b-11
Line D
Line D
Line D
Line D

Breeding Pairs

Litters

11
41
35
32
10
8
9
11

8
9
14
3
5
2
4
5

Male pups Female pups
12
22
16

18
28
25

14
3
5
10

17
3
5
10

Set ups that
produced litters
72.73
21.95
40.00
9.38
50.00
25.00
44.44
45.45

Table provides the number of Mcs1b line 1b-11 and Mcs3 line D breeding pairs
set up and the number of set ups that generated litters. It is further broken down to the
number of males and females that the litters together contained. The last column is the
percentage of set ups that resulted in litters.
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There were a total of 16 males and 25 females. To generate female rats that were
homozygous Cop at the 1b-11 locus to use in designed experiments male rats and female
rats that were homozygous Cop at the 1b-11 locus (N17F3 generation). In this case only
three of the thirty-two setups generated litters (9% of set ups). At this point, a decision
was made to stop breeding congenic line 1b-11 since it was not generating enough litters.
Analysis of Mcs3 Congenic Line D Set Ups
Generating Rats That Were Homozygous Cop at the Mcs3 Line D Locus
Rats that were homozygous Cop at the Mcs3 line D locus (N10F3 generation)
were set up to generate the N10F4 generation (Table 6). Out of 10 different set ups, five
(50% of set ups) produced litters. There were a total of 14 males and 17 females. Since
all the rats that were set up were homozygous Cop at the Mcs3 Line D locus all Mcs3 line
D litters generated were also homozygous Cop at the Mcs3 Line D locus. N10F4 rats
were set up with each other to produce the next generation (N10F5). Two out of eight set
ups (25% of set ups) generated litter. There were a total of 3 males and 3 females. N10F5
rats were set up to produce the next generation (N10F6). Four out of nine set ups (44% of
set ups) generated litter. There were a total of 5 males and 5 females. Like the previous
three generations the N10F6 generation also bred successfully to generate litters. N10F6
rats were set up with each other to produce the next generation (N10F7). Five out of
eleven set ups (45% of set ups) generated litter. There were a total of 10 males and 10
females.
Discussion
The goal of this specific aim was to narrow the Mcs1b locus and identify possible
complex genetic interactions within the locus. To achieve this goal; congenic line 1b-11
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rats were needed. However, congenic line 1b-11 did not breed successfully. Mcs3
congenic line D breeding is also analyzed to display that congenic line 1b-11 was
breeding poorly. In comparison to congenic line 1b-11, congenic Mcs3 line D always had
more than 20% of set ups generate litters with larger litter sizes. Congenic line 1b-11 rats
bred successfully when they were heterozygous Cop at the 1b-11 locus. However, most
breeders failed to generate litters when rats that were homozygous Cop at the 1b-11 locus
were bred with each other. In the event that set ups resulted in a litter, the litter either died
at birth or the female ate her litter soon after. The three litters that did survive had a small
litter size of 2 to 3 pups each. Thus, it was not feasible to generate litters that were
homozygous Cop at the 1b-11 locus.
In general, congenic rats which breed successfully produce a new generation after
four months. Congenic line 1b-11 rats were slower to breed since fewer rats were fertile
and took approximately five to six months between generations. The breeding issues
associated with congenic line 1b-11 rats were noted after eighteen to twenty four months
of breeding (four generations of breeding). It was still possible to use rats that were
heterozygous Cop at the 1b-11 locus instead of rats that were homozygous Cop at the 1b11 locus to determine if congenic line 1b-11 replicated Mcs1b associated phenotypes.
However, a larger sample size of these heterozygous rats would be needed to study the
same phenotypes. Due to the above noted difficulties in breeding congenic line 1b-11 and
time restrains, the decision was made based on advice from my dissertation committee to
not continue with this specific aim.
There are many factors that affect breeding of congenic rats, some of them
include first mating age, light intensity, stress, pheromones and diet [204-207]. The
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microenvironment comprises the immediate physical enclosure the animal is in. It
includes the cage, bedding, food and water supply. The microenvironment is also
characterized by illumination, noise, vibration, humidity, temperature and the air within
the cage. The macroenvironment comprises the physical environment of the secondary
enclosure that houses the primary enclosure. This is the room that contains the rat
housing cages. The macroenvironment is affected by the design of the animal room, the
traffic within of animal handlers, animal cages, noise, etc. Although the two
environments are associated with each other, there are differences between the two. The
temperature, humidity and illumination vary appreciably between the macro and
microenvironments. Identifying the causes that resulted in congenic line 1b-11 not
producing ample litters is beyond the scope of this project. Future research could be
directed toward addressing this problem.
Materials and Methods
Generating WF.Cop Congenic Line 1b-11
All animals used for this study were housed within the University of Louisville
Research Resources Center Animal Facility. All animal protocols were approved by the
University of Louisville IACUC.
Line 1b-11 was developed through a backcross of Mcs1b resistant WF.Cop line T
to WF rats. The resultant pups were genotyped using informative markers. The
recombinant rat with a Cop allele represented in the congenic line 1b-11 was selected and
further backcrossed to WF females to expand the line. Rats that are heterozygous Cop at
the 1b-11 locus were used in brother sister matings to inbreed the line and generate rats
that were homozygous Cop at the 1b-11 locus.

66

Genotyping
Pups were tail clipped at five to ten days of age and toe tattooed for within litter
identification. Genomic DNA was extracted to determine genotypes as described in
chapter 2. SNPs between the two strains were used for genotyping. DNA was amplified
using TaqMan genotyping master mix from Life Technologies and primers and probes
specific for SNP markers. Analysis was performed on StepOne Plus QPCR machine ABI
using the StepOne software for genotyping Analysis. Informative markers used to
genotype congenic line 1b-11 are shown in table 7.

67

Table 7. Informative Genetic Markers Used to Genotype Congenic Line 1b-11
Primer and probe Sequences for SNPs in 1b-11 locus

Samuelson Lab
ID

T
y
p
e

Forward Primer
Sequence

Reverse Primer Sequence

Probe-Copenhagen allele

Probe-Wistar-Furth allele

A12v
Allelic
Discrimination
Assay

S
N
P

CAACTCATGTT
CAGAGACATTT
T
CCT

TGTGTGGTCTTCTGTTT
TCTTGGA

VICAGACTTCTCAAACCAGMGBNFQ

6FAMAGACTTCTCCAACCAGMGBNFQ

A12oo
Allelic
Discrimination
Assay

S
N
P

AACGTTACCGC
ATTGACACTTG

CAGGCTAGCCTGGGCT
ATAAGAA

VICAAGATTTTTATTTGTTTC
AACCAG-MGBNFQ

6FAMAAGATTTTTATTTGTTT
GAACCAG-MGBNFQ

A46-SNP-A
Allelic
Discrimination
Assay

S
N
P

GCACTCCAGTG
GTAAGACTAA
AGCA

TTTACCTGGAAACGGA
ATGCA

VICAGAACTTCTACAGAACC
T- MGBNFQ

6FAMAGAACTTCTACAGGACCTMGBNFQ

A74-SNP-17
Allelic
Discrimination
Assay

S
N
P

CTGGGTCAACA
ACTCGCTGAT

GGAACGTAAGAAACGC
TGTAGAGAT

VIC- AGCTGCAAATGTCMGBNFQ

6FAMAGCTGCACATGTCATMGBNFQ
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CHAPTER IV
MCS1B CANDIDATE GENE EXPRESSION IN RAT MAMMARY EPITHELIAL
CELLS
Introduction
This chapter focuses on the investigation of mammary epithelial cell populations
(MECs) contained in congenic Mcs1b rat mammary glands. The rat Mcs1b locus was
mapped to a 1.8Mb region on rat chromosome 2 using congenic rats with Mcs1b
Copenhagen (Cop) alleles on a Wistar-Furth (WF) genetic background by denDekker et
al [137]. The Cop allele at the Mcs1b locus confers resistance to DMBA induced
mammary carcinogenesis. The Mcs1b locus acts in a mammary gland independent
manner [137]. Mammary glands from susceptible or Mcs1b resistant donor genotypes
were transplanted into the interscapular fat pads of susceptible or Mcs1b resistant
recipient rats. The recipient rats were then given a single dose of DMBA at fifty to fifty
five days of age. Tumor outcome was checked at fifteen week post DMBA administration
on the transplanted mammary gland. The donor genotype, but not the recipient genotype
had a significant effect on tumor outcome, suggesting a mammary gland independent
mechanism for the Mcs1b locus. The authors also proceeded to look for sequence
variation in open reading frames of Mcs1b encoded genes between susceptible and Mcs1b
resistant rats in an attempt to identify causative genes. No variation was identified in the
coding regions of genes in the Mcs1b locus. With this observation, it was hypothesized
that the Mcs1b variant is present in a non-coding region and is responsible for differential
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expression of Mcs1b encoded genes. Since the Mcs1b locus acts in a mammary gland
independent manner, the expression assays were performed on mammary tissue extracts.
Mitogen-Activated Protein Kinase Kinase Kinase 1 (Map3k1), GC-Rich Promoter
Binding Protein 1 (Gpbp1) and Mesoderm Induction Early Response 1, Family Member 3
(Mier3) were differentially expressed between the susceptible and Mcs1b resistant
mammary glands that were not exposed to DMBA. However, only Mier3 was
differentially expressed between susceptible and Mcs1b resistant mammary glands with
DMBA exposure. Mammary transcript levels were lower in the Mcs1b resistant
mammary glands compared to the susceptible mammary glands for all three genes. Mier3
had a higher expression in tumors as compared to adjacent disease free tissue [137]. A
Mier3 variant (Mier3-alt5’P) which uses an alternative 5’start site was also identified.
This variant had a higher expression in susceptible mammary glands as compared to
Mcs1b resistant mammary gland. Since there are two variants of Mier3 being quantified
in the rat mammary gland the variant previously referred to as Mier3 will be referred to
as the full-length variant of Mier3 and the variant with the alternate 5’ start site will be
referred to as Mier3-alt5P.
The next step of the above investigation was directed toward localizing Mier3
expression in the mammary gland. The rat mammary gland is a complex tissue. It
undergoes most of its development after birth in phases which run parallel to sexual
development and reproduction. The rudimentary mammary gland present at birth
undergoes development once puberty begins as a result of changes in sex hormone levels.
Structurally, the rat mammary gland is a tree like structure, consisting of a network of
ducts and lobules. The mammary gland develops ductal structures which consist of
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terminal end buds (TEB). These structures grow and branch throughout the mammary
gland. The TEBs consist of a hollow central lumen which is lined by layers of cells. The
lumen is surrounded by a layer of luminal epithelial cells which are surrounded by a layer
of basal epithelial or myoepithelial cells which are further lined by a basement
membrane. The tip of the growing end of TEBs consist of cap cells, which are loosely
adhering epithelial cells that lack cytoplasmic polarity, steroid receptors, and an
organized cytoskeleton [208]. Apart from the ductal structures, the mammary gland
comprises the mammary fat pad which contains fibroblasts, endothelial cells, leukocytes
and adipocytes [209]. MIER3 is an uncharacterized gene with a protein product localized
to the nucleus [137]. To visualize Mier3, Dr. Xu performed immunohistochemistry
staining for Mier3 in Mcs1b rat mammary gland tissue. He identified that Mier3 is not
uniformly expressed throughout mammary gland tissue, but is specific to a subpopulation of epithelial cells lining the duct (figure 9). Also, as mentioned above, the
Mier3 variant (Mier3-alt5’P) with an alternative 5’ transcriptional start site is
differentially expressed between Mcs1b resistant and susceptible mammary glands.
Differentially expressed 5’ start variants are typically indicative of cell or tissue type
specific expression. It is hypothesized that differential expression of Mier3 in rat
mammary epithelial cells (MECs) explains the reduced susceptibility to DMBA induced
mammary carcinogenesis in resistant Mcs1b rats compared to susceptible WF rats. To
test this hypothesis, Map3k1, Gpbp1, full-length Mier3 and Mier3-alt5’P transcript levels
were compared between mammary epithelial cell enriched extracts (MEC extracts)
obtained from Mcs1b resistant and susceptible mammary glands with and without DMBA
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exposure. In addition, the MEC extracts were also characterized by quantifying the
number of luminal and basal epithelial cells present.
Results
Immunofluorescence of Rat Mammary Gland Was Not Specific
The rat cervical mammary gland sections were stained for Mier3 (stained red in
images) and epithelial cells, which were visualized by staining with FITC conjugated
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Figure 9. Rat Mammary Gland Stained by Immunohistochemistry for Mier3. The
above tissues were stained by Dr. Xu. Cervical mammary glands were sectioned and
stained for Mier3 by immunohistochemistry. The first panel shows an H&E stained
section of the Mcs1b rat mammary gland under 10x and 20x magnification. The second
panel shows a control section stained for IgG antibody under 10x and 20x magnification.
The third panel shows a mammary tissue section stained for Mier3 antibody under 10x
and 20x magnification. Mier3 appears to be expressed in cells surrounding the duct
compared to the rest of the tissue section.
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peanut lectin (PNL) antibody (stained green in images). The microscope settings used to
visualize the tissue did not capture any tissue auto fluoresce as shown in figure 10A. The
Mier3 antibody used binds to Mier3 successfully as shown in figure 10B. However, the
Mier3 secondary antibody by itself appeared to bind tissue nonspecifically when used
without the Mier3 primary-antibody, as seen in figure 10C. The FITC conjugated PNL
antibody by itself also appeared to bind the tissue nonspecifically as well, as seen in
figure 10D. This non specificity although minimal in both cases (Figure 10C and figure
10D) was amplified to a much greater extent when the Mier3 secondary antibody was
used in conjunction with FITC conjugated PNL antibody, as represented in figure 10E.
Thus, although the Mier3 antibody appears to stain MECs in figure 10E, we cannot be
certain that the Mier3 secondary antibody and FITC conjugated PNL antibody staining
was specific.
Quantification of Luminal Epithelial and Basal Epithelial Populations within MEC
Extracts
The isolation of single cell suspensions enriched for MECs was optimized from
the protocol found in [210]. Aliquots of MEC extracts were analyzed by flow cytometry
with the aim of quantifying luminal and basal cell populations in Mcs1b and susceptible
WF rats with DMBA exposure and without. Single cells were identified from the
population based on forward and side scatter widths. Dead cells were gated out of the
single cell populations by using a viability stain. Cells that were CD45+ and CD31+ were
gated out, as these were hematopoietic and endothelial cells, respectively. Next, the
selected cell population was separated into basal and luminal cell populations, based on
CD29 and
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Figure 10. Rat Mammary Gland Immunofluorescence Images. Rat cervical mammary
gland sections were stained for Mier3 (stained red in images) and epithelial cells were
visualized by staining with FITC conjugated peanut lectin (PNL) antibody (stained green
in images). B to E show mammary gland tissues stained by different combinations of
antibodies. A is a picture of the negative control where the mammary gland is not stained
with any antibody and it shows no fluorescence. B is a picture of mammary gland tissue
stained by Mier3 primary and secondary antibody. C is a picture of mammary gland
stained only by Mier3 secondary antibody. There appears to be some non-specific
binding which is picked up by the red filter. D is a picture of mammary gland stained
only by FITC conjugated PNL antibody. There appears to be some non-specific binding
which is picked up by the green filter. E represents the rat mammary gland stained for
mammary epithelial cells by FITC conjugated PNL and Mier3 secondary antibody. The
non-specificity of the Mier3 secondary antibody seems to be amplified by the FITC
conjugated PNL. F shows mammary gland stained by FITC conjugated PNL and Mier3
primary

and

secondary
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antibodies.

CD24 expression levels. CD24+CD29hi are the basal cell population while
CD24+CD29med are the luminal cell population.
The effects of genotype and DMBA exposure on the differences in expression
levels were analyzed by performing a two-way ANOVA. This was followed by post hoc
t-tests. The results are summarized in table 8. Basal cell numbers were not different
between Mcs1b resistant and susceptible MEC extracts with DMBA exposure (p=0.7996)
or without DMBA exposure (p=0.7866). The effect of Mcs1b genotype was statistically
significant (p=0.0002) for the luminal cell population. There was also a significant effect
(p=0.0441) of DMBA exposure on the luminal cell population. When Mcs1b genotypes
were compared by exposure, luminal cell population levels were significantly different
with DMBA exposure (p=0.0193) or without DMBA exposure (0.0009). To summarize,
luminal cell numbers were higher in MEC extracts of Mcs1b resistant females as
compared to susceptible WF females.
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Table 8. Analysis of Luminal and Basal Cells from MEC Extracts Obtained at 12
Weeks of Age from Mcs1b Congenic and WF Rat Mammary Glands
Two way ANOVA p-value
Target
Mcs1b Genotype Exposure G x E
Exposure
Luminal MEC
0.0002
0.0441
0.4559 Control
DMBA
Basal MEC
0.9514
0.3202
0.7142 Control
DMBA

percent of parent population average ± SE (n)
Susceptible
Mcs1b resistant
t-Test p-value
8.68 ± 0.78 (8)
15.94 ± 1.68 (8)
0.0009
11.11 ± 1.46 (7)
23.48 ± 4.62 (8)
0.0193
22.95 ± 2.25 (8)
24.35 ± 3.25 (8)
0.7996
26.47 ± 1.84 (7)
25.89 ± 2.80 (8)
0.7866

ratio of number of cells to the parent population were square root transformed for analysis purposes

MEC extracts were analyzed by flow cytometry. Endothelial and hematopoietic cells and
dead cells were excluded from the MEC extract to generate the parent extract. The
number of luminal MECs and basal MECs were calculated as a percent of the parent
extract. Luminal and basal MECs were analyzed by performing a two way ANOVA
using Mcs1b genotype (G) and DMBA exposure (E) as independent variables. MEC cell
numbers were then compared between the genotypes under different conditions of
DMBA exposure by performing a t-Test.
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Gene Expression Analysis in MEC Populations Supports Map3k1, Gpbp1 and Mier3Alt5P as Mcs1b Candidate Genes
Previous studies from our lab discovered that full-length Mier3, Gpbp1, Map3k1
and Mier3-Alt5P were differentially expressed between susceptible WF and resistant
Mcs1b congenic mammary glands without DMBA exposure. However, only full-length
Mier3 was differentially expressed between WF and Mcs1b congenic mammary glands
with DMBA exposure. Studies from our lab also identified that Mier3-Alt5P transcript
was differentially expressed between WF and Mcs1b mammary tissue, and this difference
was

not

observed

between

spleen,

ovarian

or

thymus

tissues.

Also,

immunohistochemically stained mammary glands showed that full-length Mier3 was
more highly expressed in cells surrounding the mammary duct compared to surrounding
mammary tissue. This led to the hypothesis that Mcs1b MECs differentially expressed
full-length Mier3, Map3k1, Gpbp1 and Mier3-Alt5P compared to WF MECs. To test this
hypothesis, I performed qPCR for these genes in MEC extracts obtained from 12 week
old rats that were administered DMBA at 50-55 days of age. Mcs1b rats were compared
to susceptible WF rats. These rats were also grouped based on DMBA exposure.
The effects of genotype and DMBA exposure on the differences in expression
levels were analyzed by performing a two-way ANOVA and this was followed by post
hoc t-tests. The results are displayed in table 9. Two Mier3 probes were used to test for
two of the isoforms of Mier3 expressed in the mammary gland. The probe referred to as
Mier3 amplified the full-length variant quantified by denDekker et al whereas, Mier3alt5P referred to the variant with an alternative 5’ start site [137]. The effect of Mcs1b
genotype

was

statistically

significant
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(P

<

0.05)

for

Table 9. Analysis of Mcs1b Candidate Genes from MEC Extract Obtained at 12
Weeks of Age from Mcs1b Congenic and WF Rat Mammary Glands
Target
Map3k1

Two way ANOVA p-value
Mcs1b Genotype Exposure G x E
0.0001
0.0452
0.7883

GpBp1

0.0477

0.1199

0.0041

Mier3

0.7230

0.6785

0.1500

Mier3-Alt5P

0.0004

0.3538

0.2987

Exposure
Control
DMBA
Control
DMBA
Control
DMBA
Control
DMBA

Fold change, target vs Rplp2 ± SE (n)
Susceptible
Mcs1b resistant t-Test p-value
1.353 ± 0.138 (12) 0.871 ± 0.123 (19)
0.0170
1.848 ± 0.274 (12) 1.000 ± 0.111 (14)
0.0058
1.257 ± 0.111 (12) 0.842 ± 0.052 (19)
0.0007
1.074 ± 0.108 (12) 1.192 ± 0.088 (14)
0.4003
0.932 ± 0.124 (12) 1.216 ± 0.164 (19)
0.2250
1.274 ± 0.195 (12) 1.086 ± 0.130 (14)
0.4177
1.481 ± 0.151 (12) 0.994 ± 0.150 (19)
0.0381
1.875 ± 0.311 (12) 0.914 ± 0.126 (14)
0.0059

Mier3 refers to the full length variant of Mier3
MEC extracts were aliquoted for gene expression analysis. Expression was calculated by
performing QPCR. Differences in expression levels were analyzed by performing a two
way ANOVA using Mcs1b genotype (G) and DMBA exposure (E) as independent
variables. Expression for every gene was then compared between the genotypes under
different conditions of DMBA exposure by performing a t-Test.
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Map3k1 (p=0.0001), Gpbp1 (p=0.0477) and Mier3-Alt5P (p=0.0004). Full-length Mier3
transcript levels were not different between Mcs1b resistant and susceptible MEC
extracts with DMBA exposure (p=0.2250) or without DMBA exposure (p=0.4177).
There was a significant effect of DMBA exposure in Map3k1 levels (p=0.0452). There
was a significant interaction effect between Mcs1b genotype and DMBA exposure for
Gpbp1 (p=0.0041). When Mcs1b genotypes were compared by exposure, Map3k1
(p=0.0170), Gpbp1 (p=0.0007) and Mier3-Alt5P (p=0.0381) transcript levels were
different between genotypes in groups that were not exposed to DMBA, and only
Map3k1 (p=0.0058) and Mier3-Alt5P (p=0.0059) were different between genotypes in
groups that were exposed to DMBA. Map3k1 and Mier3-Alt5P transcript levels were
lower in resistant Mcs1b MEC extracts compared to susceptible WF MEC extracts.
Discussion
Immunofluorescent Staining of Mier3 and MECs in Rat Mammary Gland Tissue
Sections
Mammary gland tissues sections were stained with Mier3 antibody and FITC
conjugated PNL antibody to visualize Mier3 protein and MECs, respectively. Selected
filters did not reveal that any of the tissues auto-fluoresced. Further, the Mier3 antibody
used indicated successful display of sites of Mier3 expression; it seemed the Mier3
secondary and FITC conjugated PNL antibodies used were not specific. The Mier3
secondary antibody stained cells even when the primary antibody was not present. The
Mier3 secondary antibody staining was not as strong without the use of the primary
antibody. However, once FITC conjugated PNL was used in combination with the Mier3
secondary antibody, the non-specificity associated with the Mier3 secondary antibody
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and FITC conjugated PNL antibody was amplified. It appears like the secondary Mier3
antibody interacted with FITC conjugated PNL. Thus, there is non-specificity associated
with the Mier3 secondary antibody and FITC conjugated PNL. The experiment was not
continued due to the lack of time needed to troubleshoot this experiment. Future
experiments designed to identify cellular localization of Mier3 gene products would need
to address this issue and identify antibodies that are specific to Mier3 and MECs
individually and do not cross-react.
Characterization of MEC Extract
The goal of this aim was to characterize the MEC extract to support work toward
identifying the mechanism of reduced mammary cancer susceptibility associated with
Mcs1b. Two aspects of MEC extract were quantified. The number of luminal and basal
mammary epithelial cells, and transcript levels of full-length Mier3, Gpbp1, Map3k1 and
Mier3-Alt5P present in the MEC extract. The number of luminal and basal cells and fulllength Mier3, Gpbp1, Map3k1 and Mier3-Alt5P expression levels were quantified in
MEC extracts obtained from Mcs1b resistant and susceptible mammary glands with or
without DMBA exposure.
Since the year 2000, breast cancer has also been classified into molecular
subtypes based on global gene expression profiles. These five categories, namely luminal
A, luminal B, Her2-enriched, basal like and normal breast like group [211]are found
across all breast cancer stages from in situ carcinomas, inflammatory tumors, and
metastatic tumors [212]. Luminal A tumors account for about 50% of invasive breast
cancer. Luminal A tumors are estrogen receptor (ER)+, progesterone receptor (PR)+ and
Her2-. They are less proliferative, poorly sensitive to chemotherapy, but are responsive to
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hormone therapy. Luminal B tumors are ER+, PR+ and may be Her2+ or Her2-. Luminal
B tumors have low expression of hormone receptors and they account for 20% of
invasive breast cancers. Tumors that overexpress Her2/neu are usually ER-, PR- and have
high expression of Her2/neu receptors. These tumors mostly have lymph node metastasis,
are of a high grade, and account for 15% of invasive breast cancers. Basal like mammary
tumors are similar to basal epithelial and normal myoepithelial cells. It is usually ER-,
PR-, Her2/neu- and are CK5/6+ or EGFR+. They account for 15% of aggressive breast
cancers. Basal like tumors are mostly high grade invasive cancers and special subtypes of
intraductal carcinomas with good prognosis. Luminal B, Her2-enriched and basal like are
generally resistant to hormone therapy but sensitive to chemotherapy [213]. In summary,
mammary tumor subtypes are associated with tumor prognosis and therapeutic responses.
My studies indicate that Mcs1b resistant mammary glands contain a larger
population of luminal cells with or without DMBA exposure as compared to Mcs1b
susceptible mammary glands. Also, exposure to DMBA results in an increased number of
luminal epithelial cells in both Mcs1b resistant and susceptible WF mammary glands.
This indicates that because resistant rats have a larger proportion of luminal epithelial
cells with DMBA and without that more MECs might survive the DNA-damaging effects
of DMBA or the resistant genotype might be better at replacing MECs. Never the less,
results from my experiments suggest that luminal epithelial cell populations are a
potential target of DMBA carcinogenesis and functional differences in this population
may confer genetically determined differences in susceptibility. Future experiments
should be directed towards closely looking at this population for potential expression
level differences and effects on carcinogenesis.
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I also found that Map3k1, Gpbp1 and Mier3-Alt5P were differentially expressed
between Mcs1b resistant and susceptible mammary glands that had not been exposed to
DMBA. However, only Map3k1 and Mier3-Alt5P were differentially expressed between
susceptible and resistant MEC extracts after DMBA exposure. The interaction between
genotype and DMBA exposure was significant for Gpbp1 expression, but Gpbp1 was not
differentially expressed between Mcs1b resistant and susceptible mammary glands that
were exposed to DMBA. Thus, Map3k1, Gpbp1 and Mier3 are likely candidate
susceptibility genes.
MAP3K1 is a serine/threonine kinase which was identified in 1994 [214]. It is
known to be a part of ERK and JNK kinase pathways and the NF-kappa-B pathways.
Breast cancer susceptibility SNP rs889312 marks a breast cancer risk associated locus
identified by Easton et al.[131] This locus is orthologous to the rat Mcs1b locus. The
human haplotype block associated with risk contains annotated genes, MAP3K1,
C5ORF35 and MIER3. A recent study found that miRNA targeting of MAP3K1
significantly suppressed proliferation and invasion of breast cancer cells [215]. Somatic
mutations in the cancer genome atlas study found Map3k1 alterations were enriched in
the luminal A subtype of breast cancer. Map3k1 variations were mainly inactivating
frameshift deletions or insertions [216]. However, the exact role MAP3K1 plays in breast
cancer remains to be elucidated. My studies show that Map3k1 expression increases on
DMBA exposure and that Map3k1 levels are significantly lower in Mcs1b resistant MEC
extract as compared to susceptible extracts. This makes Map3k1 a strong candidate for
the Mcs1b locus.
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GPBP1 is an uncharacterized gene. It was first identified in atherosclerotic
plaques but later a more ubiquitously expressed variant was identified. It functions as a
GC-rich promoter-specific transcription factor. Thus this protein may bind DNA and
perform transcription factor activities. My experiments show that there is a significant
effect of genotype on Gpbp1 expression. DMBA exposure has the opposite effect on
Gpbp1 expression in Mcs1b resistant and WF susceptible rat MEC extracts. DMBA
causes an increase in Gpbp1 expression in Mcs1b resistant rat MEC extracts and a
decrease in expression in susceptible rat MEC extracts. The significance of this
observation is yet unknown and warrants further investigation.
Previous investigations by denDekker et al. identified Mier3 as a candidate gene,
but results from my experiments showed no variation in the full-length variant of Mier3
expression levels between genotypes, with or without DMBA exposure. However, the
alternative splice variant identified by denDekker et al. was found to follow the same
trend that was previously observed for the full-length variant of Mier3. I found that the
Mier3-alt5P was differentially expressed between Mcs1b resistant and susceptible MEC
extracts both with and without DMBA exposure. Thus, Mier3 continues to be a candidate
gene that is potentially responsible for Mcs1b associated mammary carcinoma resistance.
It is possible that Mier3-alt5P is the main Mier3 variant present in MECs such that the
difference observed by denDekker et al. in whole mammary gland tissue is now observed
in Mier3-alt3P transcripts in MECs. Alternative splicing is one of the most important
ways mammals maintain protein diversity. Alternative splicing is used to generate
multiple proteins from the same locus. There are two major advantages to alternative
splicing, it creates more functional proteins from the same mRNA and it selects the
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isoform used in the cell. Including or skipping exons usually alters protein structure and
thereby protein functions. Alternative non-coding or partially coding exons usually
harbor cis regulatory elements that control subcellular localization, stability and
translational efficiency of the encoded protein; thereby, controlling protein localization
and density. Alternate splicing is usually common during development and in cell lineage
differentiation [217, 218]. Although we are aware of the sequence variation of the Mier3
mRNA isoform, we do not have much information regarding its function.
The congenic animals used differ genetically, only at the Mcs1b locus. Resistant
female rats differentially express Mier3-alt5p, Map3k1, Gpbp1 compared to female rats
harboring a susceptible WF allele at Mcs1b. There seems to be a larger reserve of luminal
mammary epithelial cells in Mcs1b resistant mammary glands compared to susceptible
WF rats. Therefore, any one or a combination of these observed differences could be
responsible for Mcs1b associated resistance to mammary cancer. More empirical work is
necessary to determine the mechanisms by which Mier3-alt5p, Map3k1 and Gpbp1 are
working to alter mammary carcinoma susceptibility.
Materials and Methods
Generating WF.Cop Congenic Line N3
All animals used for this study were housed by the University of Louisville
Research Resources Center Animal Facility. All protocols followed were approved by the
University of Louisville IACUC.
WF.Cop line N3 was developed through a backcross of Mcs1b resistant line T to
WF rats strain. The resultant pups were genotyped using informative markers as decribed
in chapter 2 and chapter 3. The list of markers used is provided in table 10. A
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Table 10. Informative Makers Used to Genotype Congenic Line N3
Primer and probe Sequences for SNPs in N3 locus

Samuelson Lab
ID

T
y
p
e

Forward Primer
Sequence

Reverse Primer
Sequence

Probe-Copenhagen allele

Probe-Wistar-Furth allele

A12v
Allelic
Discrimination
Assay

S
N
P

CAACTCATGTTCA
GAGACATTTT
CCT

TGTGTGGTCTTCTGT
TTTCTTGGA

VICAGACTTCTCAAACCAGMGBNFQ

6FAMAGACTTCTCCAACCAGMGBNFQ

A12oo
Allelic
Discrimination
Assay

S
N
P

AACGTTACCGCAT
TGACACTTG

CAGGCTAGCCTGGG
CTATAAGAA

VICAAGATTTTTATTTGTTTC
AACCAG-MGBNFQ

6FAMAAGATTTTTATTTGTTT
GAACCAG-MGBNFQ

A46-SNP-A
Allelic
Discrimination
Assay

S
N
P

GCACTCCAGTGGT
AAGACTAAAGCA

TTTACCTGGAAACG
GAATGCA

VICAGAACTTCTACAGAACC
T- MGBNFQ

6FAMAGAACTTCTACAGGACCTMGBNFQ

A74-SNP-17
Allelic
Discrimination
Assay

S
N
P

CTGGGTCAACAAC
TCGCTGAT

GGAACGTAAGAAAC
GCTGTAGAGAT

VIC- AGCTGCAAATGTCMGBNFQ

6FAMAGCTGCACATGTCATMGBNFQ

This table displays the primer sequences along with probe sequences used to genotype
Mcs1b rats.
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recombinant rat with the Cop allele represented in the congenic line N3 was selected and
further backcrossed to WF females to expand the line. Rats that are heterozygous Cop at
the N3 locus were inbred to generate rats that were homozygous Cop at the N3 locus.
Congenic line N3 was then fixed and rats were used for experiments. Females were
administered DMBA at fifty to fifty five days of age and were euthanized at twelve
weeks of age. Cervical, abdominal and inguinal mammary glands and spleens were
collected postmortem.
Isolation of Mammary Epithelial Cell Enriched Extract
MEC extract was prepared as previously described [210]. For each rat, both
abdominal and inguinal mammary glands without lymph nodes were excised and kept
separately in GIBCO DMEM/F12 media (Invitrogen). These mammary glands were
scissor minced and digested in 10 ml of DMEM/F12 containing 0.01 g/ml of type III
Collagenase (Worthington) for 2 hours at 37˚C with gentle horizontal shaking. 0.2 mg/ml
of DNase I (Worthington) was then added to this digest for ten minutes under vigorous
shaking. This extract was then centrifuged and the supernatant fat was discarded. The
pellet was then washed with DMEM/F12. The cells were monodispersed by dissolving
the pellet in 2 ml of Hank’s balanced salt solution containing 0.025% trypsin and 6.8 mM
EDTA. This reaction was stopped after 5 minutes by adding 4 ml of DMEM/F12
containing 10% fetal bovine serum (FBS). The cells were centrifuged and resuspended in
2 ml of DMEM/F12 containing 10% FBS and passed through a 40 μm cell strainer. The
centrifuge tube was rinsed with another 2 ml of DMEM/F12 containing 10% FBS and
passed through the same 40 μm cell strainer to collect a single cell suspension of MEC
extract.
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Antibody Staining and Flow Cytometric Analysis of MEC Extract
MEC extract was stained as previously described [210]. Single cell suspensions
were stained using antirat CD24, CD29, CD31 CD45 and live/dead stain (BD
Pharmingen) antibodies. The MEC extract was centrifuged and suspended in phosphate
buffer saline (PBS). Cells were stained with 0.5 μg of each antibody per 106 cells in 200
μl PBS for 30 minutes at 4˚C in the dark. The volume was brought up to 1 ml and
centrifuged. The cells were washed and later fixed using fixation buffer (1 part 4%
formaldehyde to 3 parts PBS) for 10 minutes at room temperature. Samples were washed
and resuspended in 600 μl PBS. Cells were counted using a flow cytometer and analyzed
using FACS Diva.
Gene Expression Assays
RNA was isolated from the MEC extract using the MagMAXTM -96 Total RNA
isolation kit (Ambion). Total RNA was quantified using Nanodrop 1000 (Fisher
Scientific). cDNA was synthesized using 1μg total RNA, 0.5x RNAsecure, 5μM random
hexamers, 25ng/μL oligo(dT18), and 0.5 mM dNTPs in a final volume of 20μL. The
reaction mixtures were incubated for 5 minutes at 65º C. Then 1× first strand buffer,
100mM DTT, and 1μL Superscript III (Life Technologies) was added to each reaction
mixture. Reactions were incubated 5 m at 25º C, 1 h at 50º C, and 15 m at 70º C. TaqMan
QPCR primers and MGB probes (Applied Biosystems) (sequences are in table 11),
designed by denDekker et al. [137], were used in a 20μl TaqMan QPCR reaction. Each
reaction comprised of 1× TaqMan Buffer A (Applied Biosystems); 3.5 mM MgCl2;
dATP, dCTP, dGTP, and dTTP at 200 μM each; experimental primers at 500 nM each;
200 nM TaqMan experimental probe (Applied Biosystems) and 0.4 units of Taq Gold
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Table 11. List Primers and Probes Used for Expression Analysis in Mcs1b Rat MEC
Extracts

Rat Mcs1b Target and Rplp2 Primers and Probe Sequences Used for QPCR
Assay Name

Forw ard Primer Sequence (5' to 3')

Reverse Primer Sequence (5' to 3')

Probe Sequence (5' to 3')

Rplp2

TGAACGACTCAACAAGGTCATCA

CAACACCCTGAGCGATGACA

VIC-CTGAATGGAAAGAATATTGAG

Map3k1

TCCTCATATTGTCAGTACCGATGTC

TTGCAAGGCAAAGGCTAAGAG

6FAM-CCTGTTGAAATCAGGTATAA

Mier3

CGAAAGGTACTGCTGTAATGGAAA

GCACTCCTCTTCAGTCCAAGCT

6FAM-CGTCTCAAGAAGGAATG

Gpbp1

GAGTAGAAGAGGAGCATGAAGATGAA

TGGTGAGTACTATTGCTGTTATGCAA

6FAM-CTCAGAGAAGGATGACGAC

Mier3-Alt5P

ATGGCGGAGGCTTCCTTT

TCAAAATCATGATCCTCAGAAGACA

6FAM-AGCCCAGTTGGGTCT

This table displays the primer and probe sequences used for gene expression analysis on
Mcs1b MEC extracts. The genes analyzed are Rplp2, Map3k1, Mier3, Gpbp1 and Mier3Alt5P.
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DNA Pol (Applied Biosystems). In case of Rplp2, primers were at the concentration of
125 nM each and 200 nM rodent Rplp2 probe was used. Real-time QPCR was run on an
Applied Biosystems Step One Plus real-time PCR machine. Real-time QPCR was run at
50°C for 2 min and 95°C for 10 min and 40 cycles of 95°C for 15 sec and 60°C for 1
min. The fluorochrome FAM was used on target gene probes and VIC was used on the
rodent Rplp2 probe (Applied Biosystems). Analysis was performed by the delta-delta CT
method using Rplp2 as the internal control. Each sample measurement is an average of
three technical replicates. Data were analyzed by performing a two way ANOVA and
post hoc t-tests.
Immunofluorescence of Transverse Sections of Rat Mammary Glands
Rat right cervical mammary glands were isolated and fixed in zinc fixative for 1624 hours. The mammary glands were then transferred into 70% ethanol. The glands were
then submitted to the UofL pathology core for paraffin embedding and tissue sectioning.
Each tissue section was deparaffinized and rehydrated by transferring it successively into
decreasing concentrations of alcohol. The tissue was rinsed in water and immersed in
10mM tris EDTA and microwaved on high for 20 minutes. The tissue was allowed to
cool at room temperature and rinsed in PBS. The tissue section was blocked with PBS
containing 0.5% triton, 5% normal donkey serum. The blocking reagent was tapped out
of the slide which was then incubated with primary antibody (rabbit polyclonal Mier3ab69877- abcam, negative control for rabbit IgG Ab-1- thermoscientific, FITC
conjugated Peanut lectin (PNL)-sigma L7381, Anti-Rat CD90 BD Pharmigen) in PBS
overnight at 4˚C. The tissue was washed with PBS. The tissue was then incubated with
secondary antibody (donkey anti-rabbit Alexa Fluor 546 conjugate, ThermoFisher
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Scientific) in PBS at room temperature for 1-1.5 hours. The tissue was washed with PBS
and was permanently mounted. The tissue was visualized using a confocal microscope
and representative images were taken.
Genomics and Statistical Analysis
Quantitative PCR (QPCR) data were analyzed using the delta-delta CT method
using Rplp2 as the internal control. qPCR data were analyzed by performing a two way
ANOVA and post hoc t-tests. Independent variables for comparing mammary gland
transcript levels were genotype and DMBA exposure. The flow cytometry data were
analyzed using a two way ANOVA. Data were transformed prior to analysis by taking
the square root of the ratio of the cell count to the gated parent population. Genotype and
DMBA exposure were independent variables.
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CHAPTER V
CONCLUSION
Breast cancer is a complex disease characterized by its environment, genetic and
epigenetic components. Many approaches have been used to study the mechanisms
associated with breast cancer, each with their own advantages and disadvantages. With
every study we gain new insight into this multifaceted collection of diseases known as
breast cancer. The laboratory rat has been used extensively to study breast cancer. There
are several rat genomic loci that associate with breast cancer susceptibility. This study
focused on two such loci, namely Mcs3 and Mcs1b, using congenic rats as a model of
breast cancer susceptibility.
The Mcs3 locus was initially predicted across two peak markers D1Mit11 and
D1Wox6 on rat chromosome 1 [173]. Rat Mcs3 had not been physically confirmed; and
thus, its location on chromosome 1 hadn’t been fine-mapped. In this study, the Mcs3
locus was physically confirmed and mapped to 25.8 MB region on rat chromosome 1
using multiple congenic lines. Mcs3 is highly relevant as it contains five genes and 1 SNP
that have been associated with breast cancer susceptibility. Bioinformatic analysis of the
locus and it orthologous region in humans led to the identification of 3 candidate genes
PAK1, ILK and, IL18BP. Among these five genes PRC1, PAK1, ILK and IL18BP are
expressed both in rats and humans. PAK1 downstream pathways play an important role in
development and maintenance of metastatic phenotype in breast cancer cells. PAK1 was
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also shown to be a predictor of recurrence and tamoxifen resistance in post-menopausal
breast cancer [198]. ILK may be an important marker since increased expression of ILK is
associated with aggressive progression and poor prognosis of breast cancer [200].
IL18BP regulates the activity of interleukin 18. IL-18 expression is significantly higher in
malignant breast tumor tissue as compared to breast tissue of patients with benign breast
disease [202].
Overall, the Mcs3 congenic rats provide an experimental organism which could be
used in the future to perform functional genetic studies which can be translated to human
breast cancer. Studying the Mcs3 locus is highly relevant because the exact mechanism
by which Mcs3 contributes to mammary carcinoma susceptibility is not known. Any of
the three candidate genes mentioned above could be responsible for the reduced
mammary carcinoma susceptibility associated with Mcs3 or the Mcs3 locus could contain
a novel breast cancer susceptibility gene.
In comparison to Mcs3, considerable research had been done on the Mcs1b locus
prior to my studies involving this QTL. The Mcs1b locus had been physically confirmed
and fine mapped [181]. It was known that the Mcs1b locus acted in a mammary gland
independent manner and full-length Mier3 variant was predicted as the Mcs1b candidate
gene [137]. It was also known that Mier3 was expressed in mammary epithelial cells
surrounding mammary ducts. There was a Mier3 splice variant with an alternate 5’ start
site (Mier3-alt5P) that was more highly expressed in Mcs1b mammary glands compared
to susceptible mammary glands [137]. One of the goals of this study was to characterize
Mcs1b mammary epithelial cells with respect to proportion of luminal and basal epithelial
cells and expression of full-length Mier3, Map3k1, Gpbp1 and Mier3-alt5P compared to
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DMBA induced mammary carcinoma susceptible WF rats. This study was performed on
MEC extracts that were enriched for mammary epithelial. MEC extracts were obtained
from mammary glands by enzymatic digestion. The MEC extract was then aliquoted for
antibody staining and cytometric analysis, and qPCR expression analysis assays. In
cytometric analysis, single cells were identified from the population based on forward
and side scatter widths. Dead cells were gated out of the single cell populations by using
a viability stain. Cells that were CD45+ and CD31+ were gated out, as these were
hematopoietic and endothelial cells, respectively. Next, the selected cell population was
separated into basal and luminal cell populations, based on CD29 and CD24 expression
levels. CD24+CD29hi are the basal cell population while CD24+CD29med are the
luminal cell population
Findings from this study indicate, the proportion of luminal MECs was higher in
Mcs1b resistant MEC extracts compared to susceptible MEC extracts. The significance of
this finding is unknown. However, this observation suggests that luminal MECs are
potentially the target cells of DMBA induced carcinogenesis and future mechanistic
studies could be conducted in luminal MECs. Expression assays on MEC extracts suggest
that Map3k1, Gpbp1 and Mier3-alt5P are potential Mcs1b candidate genes [137]. Rat
Map3k1, Gpbp1 and Mier3-alt5P transcripts were expressed at a significantly lower level
in Mcs1b resistant MEC extracts as compared to susceptible MEC extract without DMBA
exposure. Both Map3k1 and Mier3-alt5P continued to remain expressed at a significantly
lower level in Mcs1b resistant MEC extracts as compared to susceptible MEC extract
with DMBA exposure. There was a significant interaction between genotype and DMBA
exposure for Gpbp1 expression. The susceptible WF and Mcs1b rats only differ in their
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genome at the Mcs1b locus. The results suggest that Map3k1, Gpbp1 and/or Mier3-alt5P
are responsible for the Mcs1b associated reduced susceptibility to DMBA induced
carcinogenesis.
MAP3K1 is a serine/threonine kinase with a role in ERK and JNK kinase
pathways, as well as the NF-kappa-B pathway. Breast cancer susceptibility associated
SNP rs889312 identified by Easton et al. is orthologous to the rat Mcs1b locus and
nominates MAP3K1, C5ORF35 and MIER3 as breast cancer susceptibility candidate
genes [131]. A recent study found that miRNA targeting of MAP3K1 significantly
suppressed proliferation and invasion of breast cancer cells [215]. GPBP1 is an
uncharacterized gene. It’s predicted function is as a GC-rich promoter-specific
transcription factor. Thus, Gpbp1 may bind DNA and perform transcription factor
activities. Previous investigations by denDekker et al. identified Mier3 as a candidate
gene, but results from my experiments showed no variation in full-length Mier3
expression levels between genotypes, with or without DMAB exposure. The fulllengthMier3 was the variant tested by denDekker et. al. However, the alternative splice
variant Mier3-alt5P was found to follow the same trend that was previously observed for
Mier3. It is possible that Mier3-alt5P is the main Mier3 variant expressed in MECs. The
Mier3-alt5P is predicted to include a casein kinase phosphorylation site at the N-terminus
compared to Mier3 protein. Although we are aware of the sequence variation of the
Mier3 mRNA isoform, we do not know its function. Therefore, Map3k1, Gpbp1 and/or
Mier3-alt5P are Mcs1b candidate genes and the luminal mammary epithelial cell
population is the likely target of DMBA carcinogenesis.
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Future Directions
In conclusion, Mcs3 was physically confirmed and mapped to a 25.8 MB region
on rat chromosome 1 and PAK1, ILK and IL18BP are potential candidate genes. The next
step for Mcs3 would be to identify if Mcs3 acts in a mammary gland independent manner.
Once that is completed, expression studies can be performed on the candidate genes
while continuing congenic studies to further fine map the Mcs3 locus in search of
potential novel breast cancer susceptibility genes.
This study suggests the luminal mammary epithelial cell population is a target cell
population of DMBA carcinogenesis in Mcs1b congenic rats, and that Map3k1, Gpbp1
and/or Mier3-alt5P are Mcs1b candidate genes. This should be further investigated by
isolating luminal mammary epithelial cells and performing expression assays to quantify
Map3k1, Gpbp1 and/or Mier3-alt5P in Mcs1b resistant mammary glands and compare
them to susceptible mammary glands.
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Personal Statement
I come from a family which has instilled in me the drive and passion to be a better
and compassionate human being. Due to lack of opportunities and difficulties, my parents
had to compromise on their choices and hence, have always wanted the best for me,
motivating me to aim higher and allowing me to pursue my calling.
I had a good academic record throughout my years in school and college, with a
steady improvement curve over the years. I was always amongst the top 5% students
during my undergraduate and graduate education. The undergraduate curriculum at
Sophia College, Mumbai provided me with strong back ground in Life Sciences and
Biochemistry. During my undergraduate I studied a wide variety of subjects which
included Physics, Immunology, Developmental Biology, Biotechnology, Genetics, Cell
Biology, Bio-Physical Chemistry, Clinical Biochemistry, Industrial Biochemistry,
Bioinformatics and other topics related to Biochemistry and Life Sciences taught by
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varieties of plant growth promoters on Vigna radiata’. The project work helped me
greatly in sharpening my research abilities and learning various techniques and its
practical application via research. I soon fully grasped that biochemistry is an
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chemical secrets of fertility, to genome sequencing, devising ways to improve immunity
against diseases like cancer and AIDS to discovering ways to extend the human life span,
the list is large.
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I came to the United States of America to pursue my Ph.D. in Biochemistry and
Molecular Biology. I am currently a graduate student working in Dr. David J.
Samuelson’s lab. ‘Genetic and environmental breast cancer susceptibility’ is the
focus of the lab. My graduate work is mainly focused on Mammary Carcinoma
Susceptibility Locus 3 (Mcs3) Mcs3 is a QTL predicted on rat chromosome1. It was
identified in a linkage analysis study and was predicted to reduce mammary carcinoma
susceptibility in rats. I have physically confirmed the Mcs3 locus and I am currently
working on fine mapping this locus to identify its physical location on rat chromosome1.
The other half of my dissertation project deals with another QTL- Mcs1b. Previous
studies from Dr. Samuelson’s lab identified Mier3 as a potential candidate gene which
could be responsible for the altered mammary carcinoma susceptibility observed in rats
with the Mcs1b Copenhagen (Cop) allele compared to the Wistar Furth (WF) allele. It is
also known that the Mcs1b locus acts in a mammary gland autonomous manner. My work
tests the hypothesis that Mcs1b rat mammary epithelial cells differentially express Mier3
compared to the susceptible WF rats.
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Graduate Student Representative at the SOM Medical council of
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Environmental Exposures Annual Meeting to be held in Cincinnati in 2011.
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and Evolution” on August 29th-30th, 2008 by Science Academy education
program INSA Delhi, ISA Bangalore, NASI Allahabad.

3) Attended lecture workshop- Frontiers in neuroscience on January 4th-5th, 2008
by Science Academy education program INSA Delhi, ISA Bangalore, NASI
Allahabad.
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4) Visited Advanced Center for Treatment, Research and Education in Cancer
(ACTREC) on an educational trip organized by Sophia College 2007-2008.
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Le S, Samuelson DJ. Mammary Carcinoma Susceptibility locus, Mcs3: Physical
confirmation and fine mapping. Manuscript writing is in progress.
The rest of my work will be added to another paper with other authors.
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2) Saasha Kareparembil, David Samuelson. A 29MB region of Mcs3, a mammary
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4) Saasha Kareparembil, Aaron Puckett, David J. Samuelson. Predicted mammary
carcinoma susceptibility QTL on RN01 named Mcs3 contributes to reduced
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recruitment 2013
5) Saasha Kareparembil, Aaron Puckett, David J. Samuelson. Predicted mammary
carcinoma susceptibility QTL on RN01 named Mcs3 contributes to reduced
mammary carcinoma susceptibility in WF.Cop congenic rats Research Louisville
2013
6) Anna Thaman, Saasha Kareparembil, David J Samuelson DJ. Breast Cancer
Susceptibility Genes: Characterizing MIER3. Research Louisville 2014
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Research Experience:
Graduate Research: Department of Biochemistry and Molecular Genetics,
University of Louisville
Mentor: Dr. David Samuelson
Dissertation Project: Genetics and Molecular Analysis of Rat mammary cancer
susceptibility
From 03-2011 to Spring 2016 (projected graduation date)
Worked extensively with rats:
- Learned how to breed rats and maintain a rat colony
- Learned how to genotype rats
- Administered carcinogen 7 12-dimethylbenz(a)anthracene (DMBA)
to rats through oral gavage and determined mammary tumor number
using surgery
- Learned how to isolate rat mammary glands and isolated mammary
epithelial cells
- Learned to isolate granulocytes from rat blood and perform
transwell assays
General laboratory techniques learned:
- PCR methods including RT-QPCR
- DNA and RNA extraction
- Flow cytometry
- Maintaining a cell culture
- miRNA estimation
- Immunohistochemistry
- Western blots
- Immunofluorescence
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